Published in final edited form as:

Exp Gerontol. 2009 March ; 44(3): 136–160. doi:10.1016/j.exger.2008.11.003.

Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: A systematic in-depth review

Eva Boes¹, Stefan Coassin¹, Barbara Kollerits¹, Iris M. Heid^{2,3}, and Florian Kronenberg¹

¹Division of Genetic Epidemiology; Department of Medical Genetics, Molecular and Clinical Pharmacology; Innsbruck Medical University, Innsbruck, Austria

²Institute of Epidemiology, Helmholtz Center Munich, German Research Center for Environmental Health, Neuherberg, Germany

³Institute of Information Management, Biometry and Epidemiology; Ludwig-Maximilians-University of Munich, Munich, Germany

Abstract

High-density lipoprotein (HDL) particles exhibit multiple antiatherogenic effects. They are key players in the reverse cholesterol transport which shuttles cholesterol from peripheral cells (e.g. macrophages) to the liver or other tissues. This complex process is thought to represent the basis for the antiatherogenic properties of HDL particles. The amount of cholesterol transported in HDL particles is measured as HDL cholesterol (HDLC) and is inversely correlated with the risk for coronary artery disease: an increase of 1 mg/dL of HDLC levels is associated with a 2% and 3% decrease of the risk for coronary artery disease in men and women, respectively. Genetically determined conditions with high HDLC levels (e.g. familial hyperalphalipoproteinemia) often coexist with longevity, and higher HDLC levels were found among healthy elderly individuals.

HDLC levels are under considerable genetic control with heritability estimates of up to 80%. The identification and characterization of genetic variants associated with HDLC concentrations can provide new insights into the background of longevity. This review provides an extended overview on the current genetic-epidemiological evidence from association studies on genes involved in HDLC metabolism. It provides a path through the jungle of association studies which are sometimes confusing due to the varying and sometimes erroneous names of genetic variants, positions and directions of associations. Furthermore, it reviews the recent findings from genome-wide association studies which have identified new genes influencing HDLC levels.

The yet identified genes together explain only a small amount of less than 10% of the HDLC variance, which leaves an enormous room for further yet to be identified genetic variants. This might be accomplished by large population-based genome-wide meta-analyses and by deep-sequencing approaches on the identified genes. The resulting findings will probably result in a re-drawing and extension of the involved metabolic pathways of HDLC metabolism.

Address of correspondence: Florian Kronenberg, MD, Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Schöpfstr. 41, A-6020 Innsbruck, AUSTRIA, Phone: (+43) 512 9003-70560, Fax: (+43) 512 9003-73560 or -73561, E-mail: Florian.Kronenberg@i-med.ac.at.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

HDL cholesterol; genetic association; candidate genes; systematic review; genome-wide association study

1. Introduction

1.1. HDL metabolism

High-density lipoproteins (HDL) are a heterogeneous group of particles composed of a core of cholesteryl ester and triglycerides surrounded by an amphipathic layer of free cholesterol, phospholipids and apolipoproteins (apo) (Klos et al., 2007).

HDL particles exhibit multiple antiatherogenic effects (Kontush et al., 2006). They shuttle cholesterol from peripheral cells (e.g. macrophages) to the liver or other tissues in need of large amounts of cholesterol (Bruce et al., 1998), an important step that relieves the peripheral cells from cholesterol burden (Figure 1). The concept for this complex process was first proposed by Glomset et al. 40 years ago (Glomset 1968) and is called reverse cholesterol transport. It is thought to represent the basis for the antiatherogenic properties of HDL (Kontush et al., 2006; Von Eckardstein et al., 2001). Furthermore, HDL has antioxidative properties due to associated antioxidative enzymes and expresses anti-inflammatory activity in various pathways.

Figure 1 illustrates the major routes of lipoprotein metabolism to allow a better understanding of the HDL metabolism (Kwan et al., 2007). HDL precursor particles are secreted as disc-shaped structures by the liver and intestine and can absorb free cholesterol from cell membranes, a process mediated by ABCA1, apoA-I and apoA-IV. While ABCA1 presents the best understood active cholesterol efflux mechanism, the HDL-mediated removal of free cholesterol from the peripheral cells is also aided by other active transporters such as ABCG1 as well as by passive diffusion which can be enhanced by plasma membrane receptors such as SCARB1 (Cavelier et al., 2006). ApoA-I is the major apolipoprotein of HDL and activates the enzyme lecithin:cholesteryl acyltransferase (LCAT), which esterifies the accepted free cholesterol to allow more efficient packaging of the cholesterol for transport. By acquisition of additional apolipoproteins, cholesteryl esters, and triglycerides, HDL₃ particles are transformed into spherical HDL₂ particles (Dieplinger et al., 1985). Reverse cholesterol transport can take three different routes. First, large HDL particles with multiple copies of apoE can be taken up by the liver via the LDL receptor (Bruce et al., 1998). Second, the accumulated cholesteryl esters from HDL can be selectively taken up by the liver mediated by SR-B1 (Acton et al., 1996). This receptor is expressed primarily in liver and nonplacental steroidogenic tissues. Third, cholesteryl esters are transferred by the cholesteryl ester transfer protein (CETP) from HDL to triglyceride-rich lipoproteins (Bruce et al., 1998). Serum HDL cholesterol levels are influenced by the complexity of these reverse cholesterol transport processes. Disturbances in the concentrations of apoproteins, function of enzymes, transport proteins, receptors, other lipoproteins, and their clearance from plasma can have a major impact on the anti-atherogenic properties in HDL.

1.2. HDLC and epidemiological evidence for antiatherogenic properties

High-density lipoprotein (HDL) particles exhibit multiple antiatherogenic effects (Kontush et al., 2006) and HDL cholesterol (HDLC) concentrations show a strong inverse correlation with the risk of coronary artery disease (CAD) (Lewington et al., 2007). Epidemiological studies highlighted the antiatherogenic function of HDLC and showed that an increase of 1 mg/dL of HDLC levels is associated with a 2% and 3% decrease of the risk for CAD in men and women,

respectively (Wilson 1990; Linsel-Nitschke et al., 2005). A recent meta-analysis (Lewington et al., 2007) including prospective observational studies with HDLC measurements available in 150,000 individuals demonstrated a strong negative association with ischemic heart disease mortality in every age group, with no evidence of a threshold beyond which higher HDL cholesterol was no longer associated with lower mortality. On average, 13 mg/dL higher HDL cholesterol was associated with about a third lower ischemic heart disease mortality. Within every age group, the strength of this association was comparable for men and women. Moreover, clinical trials have established that increasing HDLC levels by drugs could reduce CAD risk (Gotto, Jr. 2001; Manninen et al., 1988; Rubins et al., 1999; Kronenberg 2004), thus bringing longer life expectancy. This hypothesis is compatible with observations that familial hyperalphalipoproteinemia often coexists with longevity (Patsch et al., 1981), and that higher HDLC levels are found among healthy elderly aged 85-89 years as compared to those in middle-aged subjects (Nikkila et al., 1990). Accordingly, HDL and molecules involved in HDL metabolism seem to be attractive candidates for longevity-promoting factors (Arai et al., 2004).

Since HDLC levels are under considerable genetic control with heritability estimates of up to 80% (Kronenberg et al., 2002; Perusse et al., 1997; Wang et al., 2005; Goode et al., 2007), the identification and characterization of genetic variants associated with HDLC concentrations can provide useful information related to genotype-phenotype relationships and give new insights in the background of longevity.

This article reviews the current genetic-epidemiological evidence from association studies on genes involved in HDL metabolism. Genetic association studies establish estimates for a difference of mean HDLC levels among subjects with a certain genetic variant compared to the others and thus a measure of association between the genetic background and HDLC outcome in human beings. This overview should provide a path through the jungle of association studies often reporting different names and positions for the same genetic variant under study. Furthermore, the associations are sometimes reported in the direction of the “risk allele”, that is the genetic variant associated with increased CAD risk and thus lower HDLC levels, or in the direction of the “minor allele”, that is the less frequently appearing variant in the population, which may even differ between study populations. Furthermore, it reviews the recent findings from genome-wide association studies, which have identified new genes influencing HDLC levels and provides a first taste on the future. It is not intended to provide an overview on functional studies.

2. Methods on literature search

The literature search for genes previously reported for association with HDLC was performed in PubMed using search terms such as “(meta-analysis OR associat* OR epidemiolog*) AND (polymorphism OR genetic OR mutation) AND HDL AND human” with an Entrez Date in PubMed until April 2008 (EDAT: the date the citation was added to PubMed). Results were complemented by knowledge of the lipid-experienced investigators of this study.

Eligible studies for data extraction were meta-analyses, population-based studies, studies in the general population, healthy control populations, hospital-based controls, control populations selected for not having type 2 diabetes mellitus (T2DM), and case-control studies for cardiovascular disease (CVD) or T2DM. Studies which were included in a meta-analysis were only indirectly considered by showing the results of this meta-analysis in the tables instead of each single study. We did not consider studies with special patient populations other than cardiovascular disease or T2DM (e.g. patients with chronic kidney disease).

Exclusion criteria for our search were studies in a non-English language where only the abstract was available in English and small studies with less than 500 individuals.

Studies which investigated a large number of genetic variants were only considered to provide statistically significant association, if the associations were strong enough to hold for a significance level corrected for the multiple comparisons. This was usually not sufficiently accounted for in the reported associations. Moreover, we omitted studies on polymorphisms with a too low minor allele frequency (MAF) yielding less than about 30 study participants with the minor allele considering the number of individuals investigated.

If the results of a particular polymorphism of a certain study population were considered in more than one publication, only one of these publications was referenced in our tables.

A gene was considered an HDLC candidate gene if at least two eligible studies reported a statistically significant association of genetic variation within or related to the particular gene with HDLC levels. An exception from this rule was made for *LCAT* for which strong functional evidence was available combined with one large and a few small association studies.

Rarely investigated genetic variations that showed a significant association with HDLC levels in at least one large study ($n > 1000$) are listed in an additional table (Table 11).

Tables 1-11 and the Supplementary Table show the results of all eligible candidate gene association studies which were accessible in PubMed until the Entrez Date April 2008. Even though we draw our attention to the fact not to miss the most important studies, we are aware that it might not have been possible to have complete lists of all studies which deal with candidate genes for HDL cholesterol.

It should be noted that identifying the precise rs numbers of some polymorphisms was very tedious if not impossible as rs numbers were often lacking or mistakenly reported and in some of these cases we were only able to derive rs numbers by combining literature reports with databases such as HapMap or NCBI. In some cases the effect size of the investigated SNP on HDL cholesterol was only displayed in a figure and allowed only an approximate estimate of the numerical value.

For the single nucleotide polymorphisms (SNPs) of the candidate genes reported in the Tables 1-9 we imported data from HapMap and constructed an r^2 -plot using HaploView 4.1 to illustrate the correlation of the SNPs reported for each gene. For *APOA1*, *APOC3* and *PON1* no r^2 -plot was constructed since only one or none of the tabulated SNPs was available in HapMap. Furthermore, rs2303790 of *CETP* and rs2066718 of *ABCA1* are not displayed in the r^2 -plots since the MAF of these SNPs was 0.0% for the imported HapMap data.

A further chapter reviews the evidence recently derived from genome-wide association (GWA) studies. SNPs derived from these studies are not listed in Tables 1-11 but are provided in an extra table (Table 12).

3. Results from candidate gene association studies

3.1. Cholesteryl ester transfer protein (CETP)

The *CETP* gene is located on chromosome 16 and consists of 16 exons and 15 introns and is a member of the lipopolysaccharide binding protein gene family (Yamashita et al., 2001). The gene locus is highly polymorphic with several common polymorphisms as well as rare mutations (Thompson et al., 2007).

CETP is a key plasma protein that influences circulating levels of HDLC by mediating the transfer of esterified cholesterol from HDL to apoB-containing particles in exchanges for triglycerides (Tall 1993) (Figure 1). The effect of this transfer is an increase in atherogenic apoB-containing particles and a decrease of HDL (Carlquist et al., 2007). The lipid profile typically seen in subjects with CETP deficiency includes elevated HDL cholesterol levels with LDL cholesterol levels generally in the normal range (Miller et al., 2003). Complete loss of CETP activity due to mutations in the *CETP* gene can result in up to five times the normal HDLC levels, heterozygous deficiency of CETP result in milder (10-30%) increases in HDLC levels (Klos et al., 2007).

A great number of studies investigated the association of *CETP* polymorphisms with HDLC concentrations and the evidence for an association is very clear (Table 1). Although these SNPs are in strong linkage disequilibrium they are not necessarily strongly correlated (Heid et al., 2008;Thompson et al., 2007;McCaskie et al., 2007). SNPs reported in Table 1 that were genotyped in HapMap were for the most part only weakly correlated with each other (Figure 2). Some of the investigated SNPs showed pronounced additive influences on HDLC levels with changes of 2-3 mg/dL per copy of the minor allele. Meta-analyses including more than 10,000 individuals are available for rs708272 (*Taq1B*) and rs5882 (Ile405Val) showing a clear association of these SNPs with HDLC levels (Boekholdt et al., 2003;Boekholdt et al., 2005). Recently, a dense genotyping approach in more than 2000 individuals provided a very clear overview on the genetic variability within this gene and its associations with HDLC levels (Thompson et al., 2007). During the review process of this manuscript, a further meta-analysis on *CETP* was published (Thompson et al., 2008), which is not included in Table 1 since the Entrez Date in PubMed was after our deadline of April 2008. The results of this meta-analysis which included 26 to 72 studies with 39,581 to 68,134 participants for the three common SNPs rs708272 (*Taq1B*), rs5882 (I405V), and rs1800775 (-629C>A) are in line with the results of the other studies listed in Table 1 and underline the significant influence of the *CETP* gene on HDLC levels.

3.2. Lipoprotein lipase (LPL)

Lipoprotein lipase is a critical enzyme involved in lipolysis of triglyceride-rich lipoproteins, chylomicrons and VLDL (Miller et al., 2004). LPL does not act directly on HDL, but its action on triglyceride-rich lipoproteins has an important indirect effect on HDL metabolism (Lewis et al., 2005) (Figure 1). Familial LPL deficiency is a rare autosomal recessive disorder characterized by absence of LPL activity and a massive accumulation of chylomicrons in plasma. Homozygous deficiency is associated with severe hypertriglyceridemia and marked reductions in high- and low-density cholesterol levels (Klos et al., 2007).

Our literature search identified nine polymorphisms investigated for an association with HDL cholesterol (Table 2 and Supplementary Table). Most of these SNPs showed a significant association with HDLC levels (Table 2), whereas no study found a significant association for the common polymorphism rs285, which is only weakly correlated with the other SNPs (Supplementary Table and Figure 2). Five of the seven SNPs available in HapMap are located in a block of strong linkage disequilibrium (Heid et al., 2008) and especially rs320, rs326, rs13702 and rs10105606 show high correlations (Figure 2). A meta-analysis is available for four common polymorphisms which demonstrated significant associations with HDLC (Wittrup et al., 1999): the minor allele of rs328 (S447X respectively S474X according to NCBI) in >4000 individuals was associated with increased HDLC levels, whereas the minor alleles of rs268 (N291S) in almost 15,000 individuals, Gly188Glu (no rs number available) in >10,000 individuals and rs1801177 (D9N) in >5000 individuals were associated with lower HDLC levels.

3.3. Hepatic lipase (LIPC, HL, HTGL)

The human *hepatic lipase* gene, *LIPC*, is located on chromosome 15q21. It comprises 9 exons and 8 introns, and spans a length of more than 30 kb. It encodes a protein of 449 amino acids with a signal peptide of 23 amino acids (Cai et al., 1989; Ameis et al., 1990). Hepatic lipase is a glycoprotein of approximately 65 kDa and is synthesized in hepatocytes and then secreted and bound to hepatocytes and hepatic endothelial surfaces. Hepatic lipase specifically catalyzes the hydrolysis of triglycerides, diglycerides and phospholipids in native lipoproteins (Miller et al., 2003). It appears to be involved in the selective uptake of cholesterol ester from HDL (Lambert et al., 2000) (Figure 1). To date, few patients with true hepatic lipase deficiency have been identified. All individuals with complete deficiency have had elevated plasma cholesterol and triglyceride concentrations. Furthermore, deficiency is characterized by abnormally triglyceride-rich HDL and LDL particles as well as high levels of HDLC (Cohen et al., 1999; Holleboom et al., 2008).

Seven SNPs in *LIPC* were reported to be associated with HDLC levels, two of them showing a very consistent association: rs1800588 and rs2070895 (Table 3). On six of the seven SNPs data are available in HapMap, and the r^2 -plot indicates a strong correlation between three of these SNPs which are all located in the promoter region of *LIPC* (Figure 2). A meta-analysis including more than 24,000 individuals is available for rs1800588 (also described as C-514T or C-480T) showing that one or two copies of the minor allele increase HDLC levels by 1.5 and 3.5 mg/dL, respectively (Isaacs et al., 2004).

3.4. Endothelial lipase (EL, LIPG)

Endothelial lipase (encoded by the *LIPG* gene) was discovered in 1999 independently by two different laboratories (Jaye et al., 1999; Hirata et al., 1999) and is a member of the triglyceride lipase gene family. This enzyme derived its name because of its expression by endothelial cells (Jaye et al., 2004). Since overexpression of *LIPG* in mice resulted in marked reduction of HDLC levels (Jaye et al., 1999), this has led to the concept that *LIPG* may play an important role in HDL metabolism. It promotes the turnover of HDL components and it increases the catabolism of apolipoprotein A-I (Figure 1). It was proposed that the endothelial lipase together with the hepatic lipase converts large HDL particles to smaller particles by its phospholipase activity (Jaye et al., 2004). Evidence is increasing that endothelial lipase might play a role in the etiology of the lipoprotein profile characteristic of the metabolic syndrome and an increased activity of this enzyme is linked to the underlying proinflammatory state in the metabolic syndrome (Lamarche et al., 2007).

In our literature search we found five SNPs of *LIPG* which were significantly associated with HDL levels (Table 4). The evidence for an association is less strong as for *CETP*, *LPL* and *LIPC* and the studies available are much smaller than for these three genes. Four of these SNPs were available in HapMap, three of them are strongly correlated with r^2 ranging from 0.31-0.96 (Figure 2).

3.5. Lecithin:cholesterol acyltransferase (LCAT)

LCAT is associated with HDL and esterifies cholesterol in plasma (Figure 1). ApoA-I serves as a cofactor for this reaction (Miller et al., 2004; Klos et al., 2007). Important knowledge on the function of this gene was derived from patients with LCAT deficiency which results in free cholesterol and phosphatidylcholine deposition in membranes followed by corneal opacification (fish-eye disease), anemia, and renal failure (Miller et al., 2004). Homozygous LCAT deficiency is an underlying cause of two conditions: familial LCAT deficiency and fish-eye disease. While the former is associated with the complete loss of LCAT activity, the latter is associated with a change in the substrate specificity of LCAT that becomes inactive toward HDL cholesterol, while retaining its activity toward LDL cholesterol. Both conditions are

characterized by severe hypoalphalipoproteinemia, but only familial LCAT deficiency is strongly associated with premature CAD (Sviridov et al., 2007).

Even though *LCAT* is due to its physiological function an important HDL candidate gene, only few large studies investigated the possible role of this gene on HDLC levels. Five polymorphisms of *LCAT* were investigated for an association with HDLC levels, but the findings are not entirely consistent (Table 5). The two SNPs available in HapMap (rs4986970 and rs2292318) are not correlated at all with each other (Figure 2) which could explain the presence of association with HDLC for one SNP (rs2292318) and the lack of association for the other SNP (rs4986970). An influence of LCAT on HDLC levels is supported by genome-wide association studies (see below). There is an urgent need for large studies investigating the influence of common and rare genetic variations of this candidate gene on HDLC levels.

3.6. Scavenger receptor class B type 1 (SCARB1, SR-B1)

The *SCARB1* gene has been localized to chromosome 12 spanning a region of 75 kb containing 13 exons. The gene encodes a receptor protein of approximately 80 kDa, whose weight can vary based on its extent of glycosylation. *SCARB1* is highly expressed in liver and steroidogenic tissue (adrenal, ovaries, and testes) (Cao et al., 1997). It was isolated and characterized as a functional hepatic receptor for HDL (Acton et al., 1996). This receptor participates in the selective uptake of cholesterol ester (Miller et al., 2003), and binds a number of ligands with high affinity, including native HDL (Cao et al., 1997). The selective uptake involves the transfer of cholesterol from the HDL particle and the release of the lipid-poor HDL particle into the plasma (Acton et al., 1996) (Figure 1). It should be mentioned that *SCARB1* has predominantly been studied in animal models where it has been shown to control levels of plasma HDLC and non-HDL cholesterol as well as the propensity for atherosclerosis (Miller et al., 2003), but it has to be determined whether this receptor has an equally important function in humans.

Despite the obvious functional evidence for an influence of *SCARB1* on HDLC levels, the genetic-epidemiological evidence is relatively weak. Our literature search identified five polymorphic sites studied with HDLC levels with inconsistent results (Table 6). The two variants found in HapMap (rs5888 and rs5891) show no correlation with each other (Figure 2). Large genetic epidemiological studies on this gene are required before a final conclusion can be drawn.

3.7. ATP binding cassette transporter A1 (ABCA1)

The ATP binding cassette group of transporter proteins is involved in the transfer of various substances across plasma membranes, including ions, peptides, vitamins, and hormones. The ABCA1 transporter is expressed in liver, macrophages and steroidogenic tissues and plays a pivotal role in the initial phase of reverse cholesterol transport by mediating cholesterol and phospholipid efflux from macrophages to HDL (Miller et al., 2003; Cavelier et al., 2006) (Figure 1). Far more than 1000 polymorphic sites within this gene are known. We appreciate the most important knowledge on *ABCA1* and its influence on HDL metabolism to a rare monogenic recessive disorder, called Tangier disease in which patients carry homozygous mutations in *ABCA1* (Bodzioch et al., 1999; Rust et al., 1999; Brooks-Wilson et al., 1999). This causes a deposition of cholesteryl esters in the reticuloendothelial organs which results in orange-colored tonsils. Cholesterol is entrapped in macrophages due to the heavily disturbed cholesterol efflux. This results in lipid-depleted HDL particles rapidly catabolized and HDL deficiency.

Since the ABCA1 transporter plays an important physiological role in HDL metabolism, many studies attempted to show an association of this candidate gene with HDLC levels. Table 7 and the Supplementary Table list 19 SNPs of *ABCA1* that were investigated in the literature.

However, most studies did not reveal large effects of these polymorphisms on HDLC levels although many included a large number of individuals. An explanation for this failing might be that a lot of rare (population frequency below 1%) and very rare (also called “private”) mutations in *ABCA1* with strong effects for each, could sum to an important influence on HDL metabolism (Cohen et al., 2004). These rare mutations are hardly to be pinpointed by association studies due to the small number of mutation carriers even in large studies. A typical example was recently shown by the Copenhagen City Heart Study (Frikke-Schmidt et al., 2008b) which could demonstrate in more than 9000 participants a pronounced effect for four rare mutations in *ABCA1* on HDL cholesterol levels (a reduction of 17 mg/dL for heterozygotes vs noncarriers, $p < 0.001$).

The r^2 -plot of the 9 available SNPs in HapMap shows that most SNPs are only weakly correlated which suggests that the missing associations of the single SNPs with HDL levels are independent of each other (Figure 2).

3.8. Apolipoprotein A-I (APOA1)

APOA1 is located in the *APOA1/C3/C4* gene cluster on human chromosome 11q23 which harbors also *APOA5*.

As the major protein component of the HDL particle, apoA-I is an important ligand for HDL binding to cellular receptors, including scavenger receptor class B type 1 and ABCA1 (Rigotti et al., 1997; Remaley et al., 2001). Therefore, apoA-I serves as a cofactor for cholesterol esterification and is an important component of the reverse cholesterol transport (Miller et al., 2003) (Figure 1). The clinical importance of apoA-I is underscored by a premature CVD in families with *APOA1* deficiency and by a marked atherosclerosis in knockout mouse models (Miller et al., 2003). Patients carrying two functionally-relevant mutations in *APOA1* being either homozygous or compound heterozygous, have extremely rare states of complete HDLC deficiency (Funke 1997) and present with two different clinical hallmarks, namely xanthomas or corneal opacities (Von Eckardstein 2006).

In our literature search we found three SNPs (rs670, rs5069 and rs5070) which were investigated for an association with HDLC levels. Mostly, large studies found a significant association with HDLC levels, but further large studies are required (Table 8 and Supplementary Table).

3.9. Apolipoprotein C-III (APOC3)

Apolipoprotein C-III is a component of triglyceride-rich lipoproteins and HDL particle and is transferred to HDL during the hydrolysis of triglyceride-rich lipoproteins (Miller et al., 2004). The major physiological role of ApoC-III appears to be an inhibiting effect on LPL (Figure 1).

For the *APOC3* gene, data on the influence of genetic variability on HDLC levels are heterogeneous. If indeed present, the influence seems to be weak (Table 8).

3.10. Apolipoprotein A-V (APOA5)

APOA5 is located proximal to the *APOA1/C3/C4* gene cluster and was recently described by two groups (Pennacchio et al., 2001; van der Vliet et al., 2001). The human *APOA5* gene consists of four exons and codes a 369 amino acid protein, expressed only in the liver (Hubacek 2005). ApoA-V is predominantly located on TG-rich particles, chylomicrons and VLDL but also on HDL, and there is evidence that ApoA-V serves as an activator of LPL (Hubacek 2005) (Figure 1).

Among the apolipoproteins, *APOA5* is the gene with the most pronounced associations with HDLC levels. Many polymorphisms of *APOA5* were investigated in the literature, and most of them show an association with decreased levels of HDLC (Table 8). Only four SNPs are available in HapMap which are only weakly associated except rs662799 and rs651821 with a strong correlation (Figure 2).

3.11. Ghrelin (GHRL)

Ghrelin was only recently described by Kojima et al. (Kojima et al., 1999). Ghrelin is an endogenous peptide, its active form is composed of 28 aminoacids and circulates in plasma in a concentration of ~800-1000 pg/mL. Ghrelin is an orexigenic peptide predominantly produced by the stomach. Accumulating evidence suggests that ghrelin is a key regulator of body weight (Cummings et al., 2003).

Two studies found a significant inverse association of four polymorphisms with HDLC levels whereas another study found no association of five SNPs with HDLC (Table 9). The effects of the SNPs on HDLC levels seem to be independent from each other since most of the SNPs available in HapMap are not highly correlated (Figure 2).

3.12. LDL-receptor (LDLR)

The LDL-receptor is a cell surface receptor that mediates the uptake of LDL particles from the circulation via receptor-mediated endocytosis (Hobbs et al., 1990). Since this receptor plays an important role in plasma lipoprotein homeostasis (Muallem et al., 2007) (Figure 1), genetic variations in the *LDLR* gene that alter its expression could contribute to inter-individual differences in lipoprotein levels.

Some of the five literature-reported polymorphisms in the *LDLR* gene show an association with HDLC levels, which was not confirmed by other SNPs (Table 9). For the four SNPs available in HapMap, rs688 and rs5925 showed strong correlations ($r^2=0.96$) (Figure 2).

3.13. Paraoxonase 1 (PON1)

Paraoxonase 1 is a member of the paraoxonase family that includes three isoenzymes; their genes are clustered on chromosome 7q21.3-22.1 (Primo-Parmo et al., 1996). PON1, a HDL-associated enzyme, is partly responsible for the antioxidation properties of HDL by protecting low-density lipoproteins against oxidation (Mackness et al., 1991).

The *PON1* gene has two widely investigated polymorphisms, the Gln192Arg and the Met55Leu, but the results are not entirely convincing (Table 9). A strong linkage disequilibrium exists between the two polymorphisms (Arca et al., 2002).

3.14. Apolipoprotein E (APOE)

ApoE is a part of chylomicrons, VLDL, IDL and of some subspecies of HDL (Sviridov et al., 2007) (Figure 1). The role of *APOE* polymorphism in determining VLDL-LDL levels is well known, but its independent influence on HDLC concentration is still controversial (Sviridov et al., 2007).

A connection between the *APOE* polymorphism and HDLC levels was found in many but not all studies (Table 10). Since *APOE* is the best investigated of all known polymorphisms with far more than 50 publications that investigated an association with HDLC levels, we only referenced large population-based studies with more than 1000 individuals per study. Almost all of these studies found the E2 allele with increased and the E4 allele with decreased HDL levels compared to the E3 allele.

4. Results on rarely investigated genes

Table 11 provides the results on genes rarely investigated which showed a significant association with HDLC levels in at least one large study ($n > 1000$). It might be a worthwhile attempt to replicate the shown associations with HDLC in further large studies.

5. Negative results on often investigated genes

Many studies investigated the association of the *APOA4* gene and HDLC levels. The most frequently investigated polymorphisms are the T347S (rs675) and Q360H (rs5110). Especially the large studies with sample sizes above 1000 did not show a significant association of these polymorphisms with HDLC levels (data not shown).

The same holds true for *APOB*: several studies investigated the association of this gene with HDLC levels. Large studies, however, showed non-significant results (data not shown). A recent genome-wide association study with almost 18,000 individuals from 16 population-based cohorts found apoB to be associated with HDLC levels ($p = 4.4 \times 10^{-8}$) (Aulchenko et al., 2008).

6. Common versus rare variants

Common variants are those that appear in the general population with a frequency $> 1\%$ or even $> 5\%$ of subjects. These variants often show, individually, rather small associations. Kathiresan et al. illustrated, however, that a combining of the information on several of these low-impact common variants can contribute to some extent to the prediction of HDLC levels (Kathiresan et al., 2008a). They studied nine SNPs at nine loci in 5287 subjects, created a genotype score on the basis of the number of unfavorable alleles and found decreasing HDLC levels with increasing genotype scores. Another study (Zietz et al., 2006) investigated five polymorphisms in different genes and found a significant association between the number of rarely occurring genotype combinations and HDLC levels, whereas each single polymorphism was not associated with HDLC levels.

Rare variants are those that appear with $< 1\%$ in the general population. Cohen and colleagues (Cohen et al., 2004) investigated whether rare DNA sequence variants collectively contribute to variation in HDLC levels by sequencing *ABCA1*, *APOA1*, and *LCAT* in individuals from a population-based study. Nonsynonymous sequence variants were eight times more common (16% vs. 2%) in individuals with low HDLC (< 5 th percentile) than in those with high HDLC levels (> 95 th percentile). Biochemical studies indicated that most sequence variants in the low HDLC group were functionally important. The authors concluded that rare alleles with major phenotypic effects contribute significantly to low plasma HDLC levels in the general population. This seminal work started a new era with a focus on rare variants, and it is a consequent step to search these variants after a gene has been pinpointed by common variants to contribute to a certain phenotype.

Other examples for genes with rare variants having an important influence on HDLC levels are the angiopoietin-like 4 (*ANGPTL4*) gene (variant E40K, MAF=2%) which was associated with significantly higher levels of HDLC ($p = 4.0 \times 10^{-7}$) in 8726 individuals of the ARIC Study (Romeo et al., 2007) or rare variants in the alcohol dehydrogenase 2 (*ADH2*) gene (MAF=2.8%) (Whitfield et al., 2003) or in the cytochrome P450, family 3, subfamily A, polypeptide 4 (*CYP3A4*) gene (MAF=0.5%) (Yamada et al., 2007) which showed significant associations in 901 and 3787 individuals, respectively.

These studies highlight several important aspects for quantitative traits: 1) multiple common alleles influence trait variation, with each allele conferring a modest effect; 2) although each

SNP exerts a modest effect, a combination of SNPs in aggregate can have a substantial influence on HDL levels; and 3) many rare alleles of candidate genes with a strong effect of each allele might have a pronounced influence on the trait under investigation in the studied population. Considering that all common alleles together explain less than 5-10% of HDLC levels in the general population and that HDLC levels are under considerable genetic control with heritability estimates of up to 80% (Kronenberg et al., 2002; Perusse et al., 1997), leaves a wide space for rare variants as well as for genetic regulatory mechanisms not yet well understood.

7. New insights from genome-wide association studies

7.1. Advantages of genome-wide association studies

The recent introduction of microarray technology for genotyping allows the genotyping of several hundreds of thousands genetic variants in a single person in one step. This enables genome-wide association (GWA) studies by genotyping a large number of individuals with phenotypes of interest at reasonable costs. Compared to a hypothesis-driven candidate gene approach as described in the chapters above the hypothesis-free GWA studies can identify new susceptibility genes without making any *a priori* biological assumptions. They permit to identify genes involved in pathways which until now were unknown to be involved in a certain phenotype. GWA studies are therefore a new and very powerful tool to identify genetic contributors to phenotypes and have revolutionized gene hunting (for review see (Kronenberg 2008; McCarthy et al., 2008). There was never a time before in which in such a short time an unbelievable high number of genes for complex diseases and phenotypes has been identified. This holds true for complex diseases such as T2DM (Frayling 2007), cancer as well as continuous variables such as lipids.

The introduction of GWA studies allowed to leave the path of hypothesis-driven search for genes influencing lipid levels, which was based on a limited *a priori* knowledge on biological and physiological processes involved in lipid metabolism. GWA studies allow to widen the horizon and to detect new genes involved in lipid metabolism. The identification of genes, however, is strongly dependent on the power of GWA studies which is usually quite low considering the fact that 500,000 SNPs and more are investigated at once, which creates a pronounced multiple testing problem with up to 25,000 false positive findings if the conventional significance threshold of $p < 0.05$ is used. A decrease of this threshold to a genome-wide significance level (e.g. $p < 10^{-7}$) and an increase in the number of samples studied increases the power and allows to bring the “real” genes out of the jungle of false positive associations. Therefore, the step from the single study to the meta-analysis was never before as short as in times of GWA studies. The researchers in this field realized immediately that they are more successful when combining their studies, which allows to identify even gene variants modifying the disease risk by only 10% or explaining less than 0.5% of the variance of continuous parameters.

7.2. Findings on HDLC by genome-wide association studies

Until now eight GWA studies on HDLC levels are available (Willers et al., 2008; Kathiresan et al., 2008b; Kooner et al., 2008; Wallace et al., 2008; Heid et al., 2008; Kathiresan et al., 2007; Aulchenko et al., 2008; Cashman et al., 2008). Results from these studies are summarized in Table 12. On the one hand, they have confirmed the following genes which were already known from earlier functional as well as association studies: *CETP*, *LPL*, *LIPC*, *LIPG*, *ABCA1*, *LCAT*, and the *APOA1C3A4A5 gene cluster*. On the other hand, these studies have identified new candidate genes influencing HDLC levels which need further functional characterization.

The most pronounced association of these newly identified genes was observed for *GALNT2* (Willer et al., 2008; Kathiresan et al., 2008b). This gene would not have been identified in an hypothesis-driven approach since it does not have a known function immediately connected to lipid metabolism. *GALNT2* encodes a widely expressed glycosyltransferase that could potentially modify a lipoprotein or receptor. This gene was also found to be associated with triglyceride concentrations (Willer et al., 2008; Kathiresan et al., 2008b). Another newly identified gene region was located near *MVK* and *MMAB*. These neighboring genes are regulated by SREBP2. *MVK* encodes mevalonate kinase, which catalyzes an early step in cholesterol biosynthesis, and *MMAB* encodes a protein that participates in a metabolic pathway that degrades cholesterol (Willer et al., 2008). *GRIN3A* was identified in the initial GWA with a genome-wide significant p value of 2.5×10^{-8} , but was not confirmed in the combined analysis with the replication samples (Willer et al., 2008). *CLPTM1* was found in two independent GWA studies with a combined p value of 5.79×10^{-6} . However, this SNP was not found by other GWA studies (Willer et al., 2008; Heid et al., 2008; Aulchenko et al., 2008; Cashman et al., 2008).

Future GWA studies under way with even larger study samples and meta-analyses in up to 50,000 to 100,000 study participants will elucidate whether the above mentioned new genes or previously known candidate genes mentioned in chapter 3 and 4 but not yet identified in the hitherto published GWA studies will be confirmed. It can be taken for granted that new candidates will be identified with even smaller effect sizes than for the already identified genes.

Except three GWA studies (Heid et al., 2008; Cashman et al., 2008; Aulchenko et al., 2008), previous studies were mainly based on study participants ascertained for T2DM or the metabolic syndrome (Willer et al., 2008; Kathiresan et al., 2008b; Wallace et al., 2008; Kooner et al., 2008; Kathiresan et al., 2007), which could have obscured the results. Therefore, meta-analyses of population-based studies might have an advantage in identifying new candidates for HDLC levels that are not yet distorted by disease processes or medication. Such a meta-analysis of 16 European population-based cohorts has been published very recently (Aulchenko et al., 2008). For HDL cholesterol, eight regions showed genome-wide significant results. The results of the SNPs with the lowest p value for each of these regions are displayed in Table 12. Five of these regions (*LPL*, *ABCA1*, *LIPC*, *CETP*, and *LIPG*) have been identified in earlier GWA studies, *APOB* was for the first time identified in a GWA study for HDL cholesterol, and two regions (*CTCF-PRMT8* and *MADD-FOLH1*) represent entirely novel regions. The *MADD-FOLH1* locus of chromosome 11 represents a gene desert close to the centromere with no known gene on the 550 kb flanking region, and the two genes *MADD* and *FOLH1* flanking the locus have not been implicated in lipid metabolism. The *CTCF-PRMT8* gene encodes a transcriptional regulator, potentially involved in hormone-dependent gene silencing (Aulchenko et al., 2008). Further studies are needed to examine the potential role of these or neighbouring genes in HDL metabolism.

It is of interest that some loci (*LCAT*, *APOA1C3A4A5*, *GALNT2*, *MVK/MMAB*, *CLPTM1* and *GRIN3A*) identified in earlier GWA studies of mostly diseased populations could not be confirmed in the meta-analysis of 16 European population-based cohorts. It can not be excluded that they were false positives in earlier studies considering that some were of borderline significance in these studies. Another explanation could be that genetic variation in these genes might play a more pronounced role in populations with metabolic disease-relevant disturbances compared to the general population.

7.3. Conclusion from GWA studies on intergenic regions

One of the most important observation of our and other GWA studies is the fact that strong association signals are observed for SNPs in regions hitherto regarded as “intergenic”. For example, we observed for HDLC very strong signals up to 70kb downstream of *LIPG* and

LPL, and 10kb upstream of *CETP* (Heid et al., 2008). This is particularly remarkable as the usual current candidate gene studies focus on SNPs within the gene ± 5 kb. While our downstream *LPL* SNPs showed some correlation with previously literature-reported SNPs within the gene, our *LIPG* signals were completely independent from SNPs within the gene or from any SNP reported previously in candidate gene studies. The identified *CETP* SNP 10kb upstream (rs8999419) was independent from all of the numerous SNPs reported in candidate gene studies and was even located in a recombination hotspot which strongly supports this region as an independent locus.

These findings are in line with ideas that several regions within and outside of a gene can have independent effects on the gene function and that even regions far away from the gene harboring transcription factor binding sites, miRNAs, other enhancer elements or yet unknown regulatory elements can remotely control gene function. A similar example is reported for chromosomal region 9p21, which was shown to be associated with myocardial infarction (Samani et al., 2007) and T2DM (Scott et al., 2007; Saxena et al., 2007). SNPs with the most significant signals were located more than 100kb upstream of the cyclin-dependent kinase inhibitors *CDKN2A* and *CDKN2B*, which supports either long-range effects on one of these genes or the influence of a gene not yet annotated. This supports the relevance of intergenic regions and calls for future functional studies to address this issue.

As we discussed recently (Heid et al., 2008), the relevance of genetic variation far outside of the gene might have far reaching consequences for candidate gene association studies in general. It is conceivable that plausible candidate genes in the past have been dropped prematurely when no association between intragenic variation and the investigated phenotypes was observed. If these regions are not considered and the variation located there is not in strong linkage disequilibrium with intragenic variation, an association would be missed. A higher-weighting for intragenic regions in previous candidate gene studies results in a biased search of phenotype-influencing gene regions and should probably be avoided.

In line with these observations, the GWA study approach thus evolves as “*the better candidate gene study*” as it enables a much more comprehensive analysis of all known candidate genes with ad libitum extension beyond gene boundaries and comparability across studies. Previously, candidate gene studies were each investigating different SNPs in different studies with different HDLC measurements and often different analysis models and in most of the studies with a strong focus on the promoter and intragenic regions of these genes.

8. Heterogeneity of low-HDL syndromes

HDL cholesterol levels have a strong genetic determination, with heritability estimates ranging in most cases between 40% and 60% (Wang et al., 2005; Goode et al., 2007; Kronenberg et al., 2002). As it is the case with many intermediate cardiovascular risk phenotypes, low HDLC can be either monogenic or purely environmental or, in most cases is multifactorial / polygenic in origin (Von Eckardstein 2006). The most common inherited form of low HDLC is familial hypoalphalipoproteinemia, which is defined as an HDLC level below the 10th percentile, without secondary cause, and associated with a family history of low HDLC levels. The genetic cause is not fully characterized: some of the cases are due to mutations in HDL structural genes (mostly in one of the three genes *APOA1*, *LCAT* or *ABCA1*), whereas in other cases there appears to be accelerated catabolism of HDL and its apolipoproteins without a specific genetic mutation identified (Klos et al., 2007). In contrast to the rare occurrence of isolated low HDL in hypoalphalipoproteinemia, very low plasma levels of HDLC are also found in patients with genetically disturbed metabolic pathways which are indirectly linked to HDL metabolism. For example, many patients with lipid storage diseases like Gaucher’s disease, Nieman-Pick disease, diabetes mellitus or hypertriglyceridemia present with low HDL cholesterol (Von

Eckardstein 2006). In the context of high triglycerides, low HDL cholesterol is not only an early symptom, but also provides a very sensitive marker of impaired glucose tolerance and increased lipolysis (Rohrer et al., 2004). These examples reflect the very heterogeneous nature of HDLC which makes HDL genetics very complex.

9. Relationship between HDLC and triglyceride genes

Many genes control lipolysis of plasma triglycerides, a process that also affects HDLC levels through the delivery of apolipoproteins and phospholipids to HDL (Holleboom et al., 2008). There are several genes influencing both HDLC and triglyceride levels which have been identified by candidate gene and hypothesis-free GWA study approaches. For example associations between common SNPs at the *APOA5* locus and triglyceride concentrations as well as HDLC levels are significant and relatively consistent across studies and populations (Lai et al., 2005). Certain variants of *LPL* are associated with elevated plasma triglyceride and decreased HDLC levels (Busch et al., 2000). The variation of the recognition site for SstI within the 3'-untranslated region of *APOC3* has consistently shown an association with both plasma triglyceride and HDLC levels, whereas common variants of some other promising candidate genes, such as *LIPC*, were not as consistent (Busch et al., 2000).

Recent GWA analyses confirmed on the one hand the association of several loci with prior evidence of an association with triglyceride and HDLC levels (*LPL*, *APOA1C3A4A5*, and partly *LIPC*) (Saxena et al., 2007; Wallace et al., 2008; Kooner et al., 2008; Willer et al., 2008; Kathiresan et al., 2008b; Aulchenko et al., 2008; Cashman et al., 2008), and identified on the other hand new loci (*GALNT2*, *APOB*) with an influence on both HDL and triglyceride levels (Willer et al., 2008; Kathiresan et al., 2008b; Aulchenko et al., 2008).

10. HDLC genes and atherosclerosis

The epidemiological evidence for an inverse association of HDLC concentrations with the risk of coronary artery disease is very strong (Lewington et al., 2007), but the causality of this relationship is hard to prove. Since HDL levels are strongly determined by genetic variants (besides environmental factors), a causal association between HDLC and CAD can be demonstrated by showing an association of these genetic variants with risk of CAD. The idea behind is the concept of Mendelian Randomization (Katan 1986; Davey et al., 2003; Kronenberg et al., 2007) which is based on the fact that it is randomly determined at the time of conception which of the two alleles from the father as well as from the mother will be transmitted to the child. Since the transmitted alleles are of lifelong persistence, these alleles determine to a certain amount also whether a person is exposed e.g. to low HDLC levels and therefore to the CVD risk associated with low HDLC levels. Therefore, the association between the polymorphism and CVD is less influenced by reverse causation or confounding. Reverse causation would mean that CVD influences the polymorphism, which can practically be excluded. Confounding would mean that e.g. a lifestyle factor such as smoking is associated with the disease (which is often the case) as well as with the polymorphism (which is less probable). Therefore this method is well appropriate to underline a causal relationship which is hardly possible with conventional epidemiological observation studies. The idea of Mendelian Randomization was originally proposed by Katan in the mid eighties (Katan 1986) and was more and more used during the last five years (Davey et al., 2003). To our knowledge, it was the first time applied in 1992 when Sandholzer and colleagues clearly showed that the apolipoprotein(a) gene locus determines the risk for CVD by its strong influence on lipoprotein(a) concentrations (Sandholzer et al., 1992). This seminal work demonstrated that high lipoprotein(a) concentrations are a primary, genetically determined risk factor for CVD, which was discussed controversially at that time since some researchers had believed that high lipoprotein(a) concentrations are a consequence rather than a cause of CVD.

The causal relationship between lipoprotein(a) and atherosclerosis by using the Mendelian Randomization approach has been confirmed in the meanwhile by several studies (Kronenberg et al., 1999b; Kronenberg et al., 1999a; Wild et al., 1997; Kamstrup et al., 2008; Koch et al., 1997).

Figure 3A shows some considerations concerning the sample size for Mendelian Randomization projects. If one assumes that a particular polymorphism explains an unusual high 30% of an intermediate phenotype and that this intermediate phenotype explains about 10% of the clinical endpoint, it is expected that the polymorphism itself explains about 3% of the clinical endpoint ($0.30 \times 0.10 = 0.03$). Single polymorphisms of HDLC genes, however, explain at best 3% of the HDLC levels. This would mean that such a polymorphism would explain 0.3% of the clinical endpoint ($0.03 \times 0.10 = 0.003$). These considerations warn us that very large case-control studies are required to demonstrate an association between a polymorphism and a clinical endpoint. This might be the reason why although many association studies found an association between various polymorphisms and HDLC levels, most of them were markedly underpowered to consistently find an association of these polymorphisms with clinical endpoints.

A recent meta-analysis of three polymorphisms within the *CETP* gene (*Taq1B*, I405V and -629C>A) included 92 studies with up to 113,833 healthy participants, and 46 studies on 27,196 coronary cases and 55,338 controls (Thompson et al., 2008). The minor allele of each of the three polymorphisms was associated with a moderate inhibition of CETP activity and, in line with that, modestly higher HDLC levels and, most importantly, with a weakly inverse association with coronary risk. The odds ratios (OR) for coronary disease were compatible with the expected reductions in risk for equivalent increases in HDLC concentrations demonstrated in prospective studies (Lewington et al., 2007). Figure 3B illustrates these associations for the *Taq1B* polymorphism. These results clearly support a causal association of low HDLC levels with CVD. It also demonstrates that large studies are required to detect an association of this kind with certainty: the meta-analysis on the *Taq1B* polymorphism included 38 studies with a total of 19,035 cases and 32,368 controls. Since the effects of the investigated polymorphisms on HDLC levels were in the usual range expected in association studies, the results and the required sample size will be rather the rule than the exemption.

Even if the Mendelian Randomization approach worked fine e.g. for *CETP*, the situation is less clear for *ABCA1*. A large study of almost 50,000 individuals from Copenhagen showed that heterozygosity for rare loss-of-function mutations in *ABCA1* were associated with substantial, lifelong lowering of plasma levels of HDLC (-17 mg/dL). These variants, however, were not associated with an increased risk of ischemic heart disease (Frikke-Schmidt et al., 2008b). It was speculated that this might be explained by the observation that the lower HDLC levels in these loss-of-function mutations are not accompanied by high triglyceride concentrations and that low HDLC levels per se are not atherogenic. A dysfunctionality of the HDL lipoprotein not necessarily reflected in the HDLC levels could be more important than HDLC levels themselves. This is in line with another study in the Danish population showing that common non-synonymous genetic variation in *ABCA1* predicts risk of ischemic heart disease independent of HDLC concentrations (Frikke-Schmidt et al., 2008a).

11. Conclusions

Several decades of research on the genetic contribution to HDL metabolism have identified a large number of genes contributing to the antiatherogenic HDLC concentrations. The variants detected in these genes together explain only a small amount of less than 10% of the HDLC variance, but the heritability of HDLC is estimated to be up to 80%. This provides an enormous room for further yet to be identified genetic variants. This might be accomplished by genome-

wide association studies. Since the low-hanging fruits might already be detected by earlier candidate gene studies and the first genome-wide association studies, future studies in large population-based genome-wide meta-analyses will identify new genes with even smaller effects on HDLC levels. These findings will probably result in a redrawing or extension of the involved metabolic pathways of HDLC metabolism. On the other hand, in-depth analysis of particular genes by deep-sequencing approaches or similar techniques (Coassin et al., 2008) will extend the previously made observation that a large number of rare alleles considerably contributes to a complex phenotype.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Our own research discussed in this review was funded by grants from the “Genomics of Lipid-associated Disorders – GOLD” of the “Austrian Genome Research Programme GEN-AU”, the Austrian National Bank (Project 12531) and the Austrian Heart Fund to F. Kronenberg and by the German National Genome Research Net, the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ, Germany, and the NIH-subcontract from the Children’s Hospital, Boston, USA, under the prime grant 1 R01 DK075787-01A1, CFDA 93.848 supporting the work of I.M. Heid.

References

1. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 1996;271:518–520. [PubMed: 8560269]
2. Agerholm-Larsen B, Nordestgaard BG, Steffensen R, Jensen G, Tybjaerg-Hansen A. Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene. *Circulation* 2000a;101:1907–1912. [PubMed: 10779455]
3. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, Steffensen R, Nordestgaard BG. Common cholesteryl ester transfer protein mutations, decreased HDL cholesterol, and possible decreased risk of ischemic heart disease: The Copenhagen City Heart Study. *Circulation* 2000b;102:2197–2203. [PubMed: 11056092]
4. Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE. Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. *Journal of Lipid Research* 1993;34:421–428. [PubMed: 8096867]
5. Ameis D, Stahnke G, Kobayashi J, Mclean J, Lee G, Buscher M, et al. Isolation and characterization of the human hepatic lipase gene. *J Biol Chem* 1990;265:6552–6555. [PubMed: 2324091]
6. Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. *J Am Coll Cardiol* 2003;41:1972–1982. [PubMed: 12798568]
7. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. *J Atheroscler Thromb* 2005;12:240–250. [PubMed: 16205020]
8. Arai Y, Hirose N. Aging and HDL metabolism in elderly people more than 100 years old. *J Atheroscler Thromb* 2004;11:246–252. [PubMed: 15557706]
9. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, et al. PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. *Eur J Clin Invest* 2002;32:9–15. [PubMed: 11851721]
10. Aulchenko YS, Ripatti S, Lindquist I, Boomsma D, Heid I, Pramstaller PP, et al. Genome-wide association study in 16 European population cohorts: Major loci influencing lipid levels and coronary heart disease risk. *Nat Genet.* 2008

11. Bernstein MS, Costanza MC, James RW, Morris MA, Cambien F, Raoux S, et al. No physical activity × CETP 1b.-629 interaction effects on lipid profile. *Med Sci Sports Exerc* 2003;35:1124–1129. [PubMed: 12840632]
12. Blankenberg S, Tiret L, Bickel C, Schlitt A, Jungmair W, Genth-Zotz S, et al. Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease The AtheroGene case control study. *Z Kardiol* 2004;93(Suppl 4):IV16–IV23. [PubMed: 15085362]
13. Blatter Garin MC, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. *Journal of Lipid Research* 2006;47:515–520. [PubMed: 16327022]
14. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat Genet* 1999;22:347–351. [PubMed: 10431237]
15. Boekholdt SM, Sacks FM, Jukema JW, Shepherd J, Freeman DJ, McMahon AD, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation* 2005;111:278–287. [PubMed: 15655129]
16. Boekholdt SM, Souverein OW, Tanck MW, Hovingh GK, Kuivenhoven JA, Peters RI, et al. Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. *Clinical Genetics* 2006;69:263–270. [PubMed: 16542392]
17. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *J Lipid Res* 2003;44:1080–1093. [PubMed: 12639975]
18. Borggreve SE, Hillege HL, Wolffenbuttel BH, De Jong PE, Bakker SJ, van der SG, et al. The Effect of CETP -629C>A Promoter Polymorphism on HDL Cholesterol is Dependent on Serum Triglycerides. *J Clin Endocrinol Metab* 2005;90:4198–4204. [PubMed: 15840744]
19. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. *Nat Genet* 1999;22:336–345. [PubMed: 10431236]
20. Brown CM, Rea TJ, Hamon SC, Hixson JE, Boerwinkle E, Clark AG, et al. The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. *J Mol Med* 2006;84:561–572. [PubMed: 16705465]
21. Bruce C, Chouinard RA Jr, Tall AR. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport. *Annual Review of Nutrition* 1998;18:297–330.
22. Busch CP, Hegele RA. Variation of candidate genes in triglyceride metabolism. *J Cardiovasc Risk* 2000;7:309–315. [PubMed: 11143760]
23. Cai SJ, Wong DM, Chen SH, Chan L. Structure of the human hepatic triglyceride lipase gene. *Biochemistry* 1989;28:8966–8971. [PubMed: 2605236]
24. Cao G, Garcia CK, Wyne KL, Parker KL, Hobbs HH. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. *J Biol Chem* 1997;272:33068–33076. [PubMed: 9407090]
25. Carlquist J, Anderson JL. Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis. *Curr Opin Cardiol* 2007;22:352–358. [PubMed: 17556889]
26. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, Bair TL, Molhuizen HO, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. *American Heart Journal* 2003;146:1007–1014. [PubMed: 14660992]
27. Cashman DI, Paré G, Zee RYL, Parker AN, Cook NR, Buring JE, et al. Genetic loci associated with plasma concentration of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A1, and apolipoprotein B among 6382 white women in genome-wide analysis with replication. *Circulation: Cardiovascular Genetics* 2008;1:21–30.
28. Cavellier C, Lorenzi I, Rohrer L, Von Eckardstein A. Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1. *Biochimica et Biophysica Acta* 2006;1761:655–666. [PubMed: 16798073]

29. Choi HJ, Cho YM, Moon MK, Choi HH, Shin HD, Jang HC, et al. Polymorphisms in the ghrelin gene are associated with serum high-density lipoprotein cholesterol level and not with type 2 diabetes mellitus in Koreans. *J Clin Endocrinol Metab* 2006;91:4657–4663. [PubMed: 16954159]
30. Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, et al. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation* 2001;103:1198–1205. [PubMed: 11238261]
31. Coassin S, Brandstätter A, Kronenberg F. An Optimized Procedure for the Design and Evaluation of Ecotilling Assays. *BMC Genomics*. 2008
32. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. *Science* 2004;305:869–872. [PubMed: 15297675]
33. Cohen JC, Vega GL, Grundy SM. Hepatic lipase: new insights from genetic and metabolic studies. *Current Opinion in Lipidology* 1999;10:259–267. [PubMed: 10431662]
34. Corella D, Guillen M, Saiz C, Portoles O, Sabater A, Folch J, et al. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. *Journal of Lipid Research* 2002;43:416–427. [PubMed: 11893778]
35. Costanza MC, Cayanis E, Ross BM, Flaherty MS, Alvin GB, Das K, et al. Relative contributions of genes, environment, and interactions to blood lipid concentrations in a general adult population. *Am J Epidemiol* 2005;161:714–724. [PubMed: 15800263]
36. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. *Arch Surg* 2003;138:389–396. [PubMed: 12686525]
37. Davey SG, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003;32:1–22. [PubMed: 12689998]
38. de Andrade FM, Silveira FR, Arsand M, Antunes AL, Torres MR, Zago AJ, et al. Association between -250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a Southern Brazilian population. *Clinical Genetics* 2004;65:390–395. [PubMed: 15099346]
39. Dieplinger H, Zechner R, Kostner GM. The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. *Journal of Lipid Research* 1985;26:273–282. [PubMed: 3989387]
40. Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. *Atherosclerosis* 2001;159:187–192. [PubMed: 11689220]
41. Fang DZ, Liu BW. Polymorphism of HL +1075C, but not -480T, is associated with plasma high density lipoprotein cholesterol and apolipoprotein AI in men of a Chinese population. *Atherosclerosis* 2002;161:417–424. [PubMed: 11888526]
42. Frayling TM. Genome-wide association studies provide new insights into type 2 diabetes aetiology. *Nat Rev Genet* 2007;8:657–662. [PubMed: 17703236]
43. Freeman DJ, Samani NJ, Wilson V, McMahon AD, Braund PS, Cheng S, et al. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. *Eur Heart J* 2003;24:1833–1842. [PubMed: 14563342]
44. Frikke-Schmidt R, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjaerg-Hansen A. Context-dependent and invariant associations between lipids, lipoproteins, and apolipoproteins and apolipoprotein E genotype. *Journal of Lipid Research* 2000;41:1812–1822. [PubMed: 11060351]
45. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Steffensen R, Tybjaerg-Hansen A. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. *Arteriosclerosis, Thrombosis and Vascular Biology* 2008a;28:180–186.
46. Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. *J Clin Invest* 2004;114:1343–1353. [PubMed: 15520867]

47. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA* 2008b;299:2524–2532. [PubMed: 18523221]
48. Fukuda M, Ohkubo T, Katsuya T, Hozawa A, Asai T, Matsubara M, et al. Association of a mast cell chymase gene variant with HDL cholesterol, but not with blood pressure in the Ohasama study. *Hypertens Res* 2002;25:179–184. [PubMed: 12047032]
49. Funke H. Genetic determinants of high density lipoprotein levels. *Current Opinion in Lipidology* 1997;8:189–196. [PubMed: 9211068]
50. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. *J Lipid Res* 1968;9:155–167. [PubMed: 4868699]
51. Goode EL, Cherny SS, Christian JC, Jarvik GP, de AM. Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. *Twin Res Hum Genet* 2007;10:703–711. [PubMed: 17903110]
52. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. *Circulation* 2001;103:2213–2218. [PubMed: 11331265]
53. Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C, et al. *APOA5* variants and metabolic syndrome in Caucasians. *Journal of Lipid Research* 2007;48:2614–2621. [PubMed: 17768309]
54. Grarup N, Andreassen CH, Andersen MK, Albrechtsen A, Sandbaek A, Lauritzen T, et al. The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects. *J Clin Endocrinol Metab* 2008;93:2294–2299. [PubMed: 18364377]
55. Gronroos P, Raitakari OT, Kahonen M, Hutri-Kahonen N, Marniemi J, Viikari J, et al. Influence of apolipoprotein E polymorphism on serum lipid and lipoprotein changes: a 21-year follow-up study from childhood to adulthood. The Cardiovascular Risk in Young Finns Study. *Clin Chem Lab Med* 2007;45:592–598. [PubMed: 17484618]
56. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. *Arteriosclerosis, Thrombosis and Vascular Biology* 1995;15:861–871.
57. Heid IM, Boes E, Müller AM, Kollerits B, Lamina C, Coassin S, et al. A genome-wide association analysis of HDL cholesterol in the population-based KORA Study sheds new light on intergenic regions. *Circulation: Cardiovascular Genetics*. 2008
58. Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, et al. Cloning of a unique lipase from endothelial cells extends the lipase gene family. *J Biol Chem* 1999;274:14170–14175. [PubMed: 10318835]
59. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. *Annu Rev Genet* 1990;24:133–170. [PubMed: 2088165]
60. Hodoglugil U, Williamson DW, Huang Y, Mahley RW. Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. *Atherosclerosis* 2005;183:199–212. [PubMed: 15935359]
61. Holleboom AG, Vergeer M, Hovingh GK, Kastelein JJ, Kuivenhoven JA. The value of HDL genetics. *Current Opinion in Lipidology* 2008;19:385–394. [PubMed: 18607186]
62. Holmer SR, Hengstenberg C, Mayer B, Doring A, Lowel H, Engel S, et al. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. *Cardiovasc Res* 2000;47:806–812. [PubMed: 10974229]
63. Hsu LA, Ko YL, Chang CJ, Hu CF, Wu S, Teng MS, et al. Genetic variations of apolipoprotein A5 gene is associated with the risk of coronary artery disease among Chinese in Taiwan. *Atherosclerosis* 2006;185:143–149. [PubMed: 16054149]
64. Hsu LA, Ko YL, Wu S, Teng MS, Peng TY, Chen CF, et al. Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese. *Arteriosclerosis, Thrombosis and Vascular Biology* 2003;23:1869–1874.

65. Hubacek JA. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. *Clin Chem Lab Med* 2005;43:897–902. [PubMed: 16176166]
66. Hubacek JA, Bohuslavova R, Skodova Z, Adamkova V. Variants within the ghrelin gene--association with HDL-cholesterol, but not with body mass index. *Folia Biol (Praha)* 2007;53:202–206. [PubMed: 18070417]
67. Hubacek JA, Skodova Z, Adamkova V, Lanska V, Poledne R. Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol. *Metabolism* 2005;54:1632–1635. [PubMed: 16311097]
68. Hutter CM, Austin MA, Farin FM, Viernes HM, Edwards KL, Leonetti DL, et al. Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. *Atherosclerosis* 2006;185:78–86. [PubMed: 16023652]
69. Iijima H, Emi M, Wada M, Daimon M, Toriyama S, Koyano S, et al. Association of an intronic haplotype of the LIPC gene with hyperalphalipoproteinemia in two independent populations. *J Hum Genet* 2008;53:193–200. [PubMed: 18160998]
70. Isaacs A, Aulchenko YS, Hofman A, Sijbrands EJ, Sayed-Tabatabaei FA, Klungel OH, et al. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. *J Clin Endocrinol Metab* 2007;92:2680–2687. [PubMed: 17440012]
71. Isaacs A, Sayed-Tabatabaei FA, Njajou OT, Witteman JC, Van Duijn CM. The -514 C->T hepatic lipase promoter region polymorphism and plasma lipids: a meta-analysis. *J Clin Endocrinol Metab* 2004;89:3858–3863. [PubMed: 15292318]
72. Jaye M, Krawiec J. Endothelial lipase and HDL metabolism. *Current Opinion in Lipidology* 2004;15:183–189. [PubMed: 15017361]
73. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, et al. A novel endothelial-derived lipase that modulates HDL metabolism. *Nat Genet* 1999;21:424–428. [PubMed: 10192396]
74. Kamboh MI, Aston CE, Nestlerode CM, McAllister AE, Hamman RF. Haplotype analysis of two APOA1/MspI polymorphisms in relation to plasma levels of apo A-I and HDL-cholesterol. *Atherosclerosis* 1996;127:255–262. [PubMed: 9125316]
75. Kamboh MI, Bunker CH, Aston CE, Nestlerode CS, McAllister AE, Ukoli FA. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African blacks. *Genet Epidemiol* 1999;16:205–222. [PubMed: 10030402]
76. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Apolipoprotein(a) pentanucleotide repeat polymorphism, lipoprotein(a) levels and risk of ischemic heart disease. *J Clin Endocrinol Metab*. 2008
77. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. *Lancet* 1986;1:507–508. [PubMed: 2869248]
78. Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB, et al. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. *Arteriosclerosis, Thrombosis and Vascular Biology* 1996;16:918–925.
79. Kathiresan S, Manning AK, Demissie S, D'Agostino RB, Surti A, Guiducci C, et al. A genome-wide association study for blood lipid phenotypes in the Framingham Heart Study. *BMC Med Genet* 2007;8(Suppl 1):S17. [PubMed: 17903299]
80. Kathiresan S, Melander O, Anevski D, Guiducci C, Burt NP, Roos C, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N Engl J Med* 2008a;358:1240–1249. [PubMed: 18354102]
81. Kathiresan S, Melander O, Guiducci C, Surti A, Burt NP, Rieder MJ, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat Genet* 2008b;40:189–197. [PubMed: 18193044]
82. Katsuya T, Baba S, Ishikawa K, Mannami T, Fu Y, Inamoto N, et al. Epsilon 4 allele of apolipoprotein E gene associates with lower blood pressure in young Japanese subjects: the Suita Study. *J Hypertens* 2002;20:2017–2021. [PubMed: 12359980]
83. Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, et al. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C->A polymorphism and a novel

- promoter variant are independently associated with CETP concentration. *Hum Mol Genet* 2003;12:111–123. [PubMed: 12499392]
84. Klos KL, Kullo IJ. Genetic determinants of HDL: monogenic disorders and contributions to variation. *Curr Opin Cardiol* 2007;22:344–351. [PubMed: 17556888]
 85. Klos KL, Sing CF, Boerwinkle E, Hamon SC, Rea TJ, Clark A, et al. Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants. *Arteriosclerosis, Thrombosis and Vascular Biology* 2006;26:1828–1836.
 86. Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS. The interactive effects of hepatic lipase gene promoter polymorphisms with sex and obesity on high-density-lipoprotein cholesterol levels in Taiwanese-Chinese. *Atherosclerosis* 2004;172:135–142. [PubMed: 14709367]
 87. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. *Journal of the American Society of Nephrology* 1997;8:1889–1898. [PubMed: 9402091]
 88. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 1999;402:656–660. [PubMed: 10604470]
 89. Komurcu-Bayrak E, Onat A, Poda M, Humphries SE, Acharya J, Hergenc G, et al. The S447X variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid levels among Turks. *Clinica Chimica Acta* 2007;383:110–115.
 90. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. *Pharmacol Rev* 2006;58:342–374. [PubMed: 16968945]
 91. Kooner JS, Chambers JC, Guilar-Salinas CA, Hinds DA, Hyde CL, Warnes GR, et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nat Genet* 2008;40:149–151. [PubMed: 18193046]
 92. Kronenberg F. Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease. *Expert Rev Cardiovasc Ther* 2004;2:729–743. [PubMed: 15350174]
 93. Kronenberg F. Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. *Exp Gerontol* 2008;43:39–43. [PubMed: 17967522]
 94. Kronenberg F, Coon H, Ellison RC, Borecki IB, Arnett DK, Province MA, et al. Segregation analysis of HDL cholesterol in the NHLBI Family Heart Study and in Utah pedigrees. *Eur J Hum Genet* 2002;10:367–374. [PubMed: 12080388]
 95. Kronenberg F, Heid IM. Genetik intermediärer Phänotypen. *Medizinische Genetik* 2007;19:304–308.
 96. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: prospective results from the Bruneck Study. *Circulation* 1999a;100:1154–1160. [PubMed: 10484534]
 97. Kronenberg F, Neyer U, Lhotta K, Trenkwalder E, Auinger M, Pribasniig A, et al. The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. *Journal of the American Society of Nephrology* 1999b;10:1027–1036. [PubMed: 10232689]
 98. Kwan BCH, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. *Journal of the American Society of Nephrology* 2007;18:1246–1261. [PubMed: 17360943]
 99. Lahiry P, Ban MR, Pollex RL, Feldman RD, Sawyez CG, Huff MW, et al. Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. *Int J Circumpolar Health* 2007;66:390–400. [PubMed: 18274205]
 100. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, et al. Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study. *J Lipid Res* 2004;45:2096–2105. [PubMed: 15342688]
 101. Lai CQ, Parnell LD, Ordovas JM. The APOA1/C3/A4/A5 gene cluster, lipid metabolism and cardiovascular disease risk. *Current Opinion in Lipidology* 2005;16:153–166. [PubMed: 15767855]
 102. Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, et al. The apolipoprotein A5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. *Journal of Lipid Research* 2003;44:2365–2373. [PubMed: 12951359]

103. Lamarche B, Paradis ME. Endothelial lipase and the metabolic syndrome. *Current Opinion in Lipidology* 2007;18:298–303. [PubMed: 17495604]
104. Lambert G, Amar MJ, Martin P, Fruchart-Najib J, Foger B, Shamburek RD, et al. Hepatic lipase deficiency decreases the selective uptake of HDL-cholesteryl esters in vivo. *J Lipid Res* 2000;41:667–672. [PubMed: 10787427]
105. Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, et al. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. *Clin Genet* 2002;61:176–184. [PubMed: 12000358]
106. Lee J, Tan CS, Chia KS, Tan CE, Chew SK, Ordovas JM, et al. The lipoprotein lipase S447X polymorphism and plasma lipids: interactions with APOE polymorphisms, smoking, and alcohol consumption. *Journal of Lipid Research* 2004;45:1132–1139. [PubMed: 15060087]
107. Legry V, Cotel D, Ferrieres J, Chinetti G, Deroide T, Staels B, et al. Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations. *Int J Obes (Lond)* 2008;32:421–428. [PubMed: 18209740]
108. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* 2007;370:1829–1839. [PubMed: 18061058]
109. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circ Res* 2005;96:1221–1232. [PubMed: 15976321]
110. Linsel-Nitschke P, Tall AR. HDL as a target in the treatment of atherosclerotic cardiovascular disease. *Nat Rev Drug Discov* 2005;4:193–205. [PubMed: 15738977]
111. Love-Gregory L, Sherva R, Sun L, Wasson J, Schappe T, Doria A, et al. Variants in the CD36 gene associate with the metabolic syndrome and high-density lipoprotein cholesterol. *Hum Mol Genet* 2008;17:1695–1704. [PubMed: 18305138]
112. Ludwig EH, Mahley RW, Palaoglu E, Ozbayrakci S, Balestra ME, Borecki IB, et al. DGAT1 promoter polymorphism associated with alterations in body mass index, high density lipoprotein levels and blood pressure in Turkish women. *Clin Genet* 2002;62:68–73. [PubMed: 12123490]
113. Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. *Proceedings of the National Academy of Sciences of the United States of America* 2003;100:2748–2753. [PubMed: 12601178]
114. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett* 1991;286:152–154. [PubMed: 1650712]
115. Mank-Seymour AR, Durham KL, Thompson JF, Seymour AB, Milos PM. Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. *Biochimica et Biophysica Acta* 2004;1636:40–46. [PubMed: 14984737]
116. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. *JAMA* 1988;260:641–651. [PubMed: 3164788]
117. Manresa JM, Zamora A, Tomas M, Senti M, Fito M, Covas MI, et al. Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. *Eur J Cardiovasc Prev Rehabil* 2006;13:738–744. [PubMed: 17001213]
118. Martin GR, Loredó JC, Sun G. Lack of association of ghrelin precursor gene variants and percentage body fat or serum lipid profiles. *Obesity (Silver Spring)* 2008;16:908–912. [PubMed: 18239581]
119. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. *Nat Rev Genet* 2008;9:356–369. [PubMed: 18398418]
120. McCaskie PA, Beilby JP, Chapman CM, Hung J, McQuillan BM, Thompson PL, et al. Cholesteryl ester transfer protein gene haplotypes, plasma high-density lipoprotein levels and the risk of coronary heart disease. *Human Genetics* 2007;121:401–411. [PubMed: 17287950]
121. McCaskie PA, Cadby G, Hung J, McQuillan BM, Chapman CM, Carter KW, et al. The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. *Clin Genet* 2006;70:114–121. [PubMed: 16879193]

122. Miettinen HE, Gylling H, Tenhunen J, Virtamo J, Jauhiainen M, Huttunen JL, et al. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia - A novel Gly²³⁰Arg mutation (LCAT_{Fin}) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. *Arteriosclerosis, Thrombosis and Vascular Biology* 1998;18:591–598.
123. Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A. Genetics of HDL regulation in humans. *Current Opinion in Lipidology* 2003;14:273–279. [PubMed: 12840658]
124. Miller M, Zhan M. Genetic determinants of low high-density lipoprotein cholesterol. *Curr Opin Cardiol* 2004;19:380–384. [PubMed: 15218400]
125. Morabia A, Ross BM, Costanza MC, Cayanis E, Flaherty MS, Alvin GB, et al. Population-based study of SR-BI genetic variation and lipid profile. *Atherosclerosis* 2004;175:159–168. [PubMed: 15186961]
126. Muallem H, North KE, Kakoki M, Wojczynski MK, Li X, Grove M, et al. Quantitative effects of common genetic variations in the 3'UTR of the human LDL-receptor gene and their associations with plasma lipid levels in the Atherosclerosis Risk in Communities study. *Human Genetics* 2007;121:421–431. [PubMed: 17273844]
127. Nakamura Y, Amamoto K, Tamaki S, Okamura T, Tsujita Y, Ueno Y, et al. Genetic variation in aldehyde dehydrogenase 2 and the effect of alcohol consumption on cholesterol levels. *Atherosclerosis* 2002;164:171–177. [PubMed: 12119207]
128. Nettleton JA, Steffen LM, Ballantyne CM, Boerwinkle E, Folsom AR. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. *Atherosclerosis* 2007;194:e131–e140. [PubMed: 17157861]
129. Nikkila M, Heikkinen J. High-density lipoprotein cholesterol and longevity. *Age Ageing* 1990;19:119–124. [PubMed: 2337007]
130. Ordoas JM, Cupples LA, Corella D, Otvos JD, Osgood D, Martinez A, et al. Association of Cholesteryl Ester Transfer Protein-TaqIB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk : The Framingham Study. *Arteriosclerosis, Thrombosis and Vascular Biology* 2000;20:1323–1329.
131. Osgood D, Corella D, Demissie S, Cupples LA, Wilson PW, Meigs JB, et al. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. *J Clin Endocrinol Metab* 2003;88:2869–2879. [PubMed: 12788901]
132. Pallaud C, Gueguen R, Sass C, Grow M, Cheng S, Siest G, et al. Genetic influences on lipid metabolism trait variability within the Stanislas Cohort. *Journal of Lipid Research* 2001;42:1879–1890. [PubMed: 11714857]
133. Paradis ME, Couture P, Bosse Y, Despres JP, Perusse L, Bouchard C, et al. The T111I mutation in the EL gene modulates the impact of dietary fat on the HDL profile in women. *J Lipid Res* 2003;44:1902–1908. [PubMed: 12867537]
134. Pare G, Serre D, Brisson D, Anand SS, Montpetit A, Tremblay G, et al. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. *American Journal of Human Genetics* 2007;80:673–682. [PubMed: 17357073]
135. Patsch W, Kuisk I, Glueck C, Schonfeld G. Lipoproteins in familial hyperalphalipoproteinemia. *Arteriosclerosis* 1981;1:156–161. [PubMed: 7295190]
136. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, et al. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. *Science* 2001;294:169–173. [PubMed: 11588264]
137. Perusse L, Rice T, Despres JP, Bergeron J, Province MA, Gagnon J, et al. Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997;17:3263–3269.
138. Porchay I, Pean F, Bellili N, Royer B, Cogneau J, Chesnier MC, et al. ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. study. *Obesity (Silver Spring)* 2006;14:1874–1879. [PubMed: 17135600]

139. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. *Genomics* 1996;33:498–507. [PubMed: 8661009]
140. Qi L, Liu S, Rifai N, Hunter D, Hu FB. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. *Atherosclerosis* 2007;192:204–210. [PubMed: 16781717]
141. Radha V, Mohan V, Vidya R, Ashok AK, Deepa R, Mathias RA. Association of lipoprotein lipase Hind III and Ser 447 Ter polymorphisms with dyslipidemia in Asian Indians. *Am J Cardiol* 2006;97:1337–1342. [PubMed: 16635607]
142. Remaley AT, Stonik JA, Demosky SJ, Neufeld EB, Bocharov AV, Vishnyakova TG, et al. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. *Biochemical and Biophysical Research Communications* 2001;280:818–823. [PubMed: 11162594]
143. Rigotti A, Trigatti B, Babitt J, Penman M, Xu S, Krieger M. Scavenger receptor BI--a cell surface receptor for high density lipoprotein. *Current Opinion in Lipidology* 1997;8:181–188. [PubMed: 9211067]
144. Rios DL, D'Onofrio LO, Cerqueira CC, Bonfim-Silva R, Carvalho HG, Santos-Filho A, et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. *Clin Chem Lab Med* 2007;45:874–878. [PubMed: 17617030]
145. Roberts CG, Shen H, Mitchell BD, Damcott CM, Shuldiner AR, Rodriguez A. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. *Hum Hered* 2007;64:107–113. [PubMed: 17476110]
146. Rohrer L, Hersberger M, Von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. *Current Opinion in Lipidology* 2004;15:269–278. [PubMed: 15166782]
147. Romeo S, Pennacchio LA, Fu Y, Boerwinkle E, Tybjaerg-Hansen A, Hobbs HH, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. *Nat Genet* 2007;39:513–516. [PubMed: 17322881]
148. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1999;341:410–418. [PubMed: 10438259]
149. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, et al. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. *Atherosclerosis* 2001;158:173–181. [PubMed: 11500189]
150. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet* 1999;22:352–355. [PubMed: 10431238]
151. Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide Association Analysis of Coronary Artery Disease. *New England Journal of Medicine* 2007;357:443–453. [PubMed: 17634449]
152. Sandhofer A, Tatarczyk T, Laimer M, Ritsch A, Kaser S, Paulweber B, et al. The Taq1B-variant in the Cholesteryl Ester-Transfer Protein Gene and the Risk of Metabolic Syndrome. *Obesity (Silver Spring)* 2008;16:919–922. [PubMed: 18239576]
153. Sandholzer C, Saha N, Kark JD, Rees A, Jaross W, Dieplinger H, et al. Apo(a) isoforms predict risk for coronary heart disease: a study in six populations. *Arteriosclerosis and Thrombosis* 1992;12:1214–1226. [PubMed: 1390593]
154. Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science* 2007;316:1331–1336. [PubMed: 17463246]
155. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. *Science* 2007;316:1341–1345. [PubMed: 17463248]

156. Senti M, Elosua R, Tomas M, Sala J, Masia R, Ordovas JM, et al. Physical activity modulates the combined effect of a common variant of the lipoprotein lipase gene and smoking on serum triglyceride levels and high-density lipoprotein cholesterol in men. *Human Genetics* 2001;109:385–392. [PubMed: 11702219]
157. Senti M, Tomas M, Elosua R, Sala J, Masia R, Marrugat J. The paraoxonase-1 codon 192 polymorphism is associated with fasting total cholesterol and LDL-cholesterol concentrations only in postmenopausal women. The REGICOR study. *Clin Chem Lab Med* 2002;40:677–683. [PubMed: 12241013]
158. Shioji K, Mannami T, Kokubo Y, Goto Y, Nonogi H, Iwai N. An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese. *J Hum Genet* 2004a;49:433–439. [PubMed: 15258834]
159. Shioji K, Nishioka J, Naraba H, Kokubo Y, Mannami T, Inamoto N, et al. A promoter variant of the ATP-binding cassette transporter A1 gene alters the HDL cholesterol level in the general Japanese population. *J Hum Genet* 2004b;49:141–147. [PubMed: 14986172]
160. Slioter AJ, Bots ML, Havekes LM, del Sol AI, Cruts M, Grobbee DE, et al. Apolipoprotein E and carotid artery atherosclerosis: the Rotterdam study. *Stroke* 2001;32:1947–1952. [PubMed: 11546879]
161. Spencer-Jones NJ, Ge D, Snieder H, Perks U, Swaminathan R, Spector TD, et al. AMP-kinase alpha2 subunit gene PRKAA2 variants are associated with total cholesterol, low-density lipoprotein-cholesterol and high-density lipoprotein-cholesterol in normal women. *J Med Genet* 2006;43:936–942. [PubMed: 16801347]
162. Srinivasan SR, Ehnholm C, Elkasabany A, Berenson G. Influence of apolipoprotein E polymorphism on serum lipids and lipoprotein changes from childhood to adulthood: the Bogalusa Heart Study. *Atherosclerosis* 1999;143:435–443. [PubMed: 10217374]
163. Srinivasan SR, Li S, Chen W, Tang R, Bond MG, Boerwinkle E, et al. Q192R polymorphism of the paraoxanase 1 gene and its association with serum lipoprotein variables and carotid artery intima-media thickness in young adults from a biracial community. The Bogalusa Heart Study. *Atherosclerosis* 2004;177:167–174. [PubMed: 15488880]
164. Stene MC, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Zinc Finger Protein 202, genetic variation, and HDL cholesterol in the general population. *J Lipid Res* 2006;47:944–952. [PubMed: 16467280]
165. Sviridov D, Nestel PJ. Genetic factors affecting HDL levels, structure, metabolism and function. *Current Opinion in Lipidology* 2007;18:157–163. [PubMed: 17353664]
166. Tai ES, Corella D, urenberg-Yap M, Adiconis X, Chew SK, Tan CE, et al. Differential effects of the C1431T and Pro12Ala PPARGgamma gene variants on plasma lipids and diabetes risk in an Asian population. *J Lipid Res* 2004;45:674–685. [PubMed: 14729856]
167. Tai ES, Corella D, urenberg-Yap M, Cutter J, Chew SK, Tan CE, et al. Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. *J Nutr* 2003a;133:3399–3408. [PubMed: 14608050]
168. Tai ES, Ordovas JM, Corella D, urenberg-Yap M, Chan E, Adiconis X, et al. The TaqIB and -629C>A polymorphisms at the cholesteryl ester transfer protein locus: associations with lipid levels in a multiethnic population. The 1998 Singapore National Health Survey. *Clinical Genetics* 2003b; 63:19–30. [PubMed: 12519368]
169. Takagi S, Baba S, Iwai N, Fukuda M, Katsuya T, Higaki J, et al. The aldehyde dehydrogenase 2 gene is a risk factor for hypertension in Japanese but does not alter the sensitivity to pressor effects of alcohol: the Suita study. *Hypertens Res* 2001;24:365–370. [PubMed: 11510748]
170. Tall AR. Plasma cholesteryl ester transfer protein. *Journal of Lipid Research* 1993;34:1255–1274. [PubMed: 8409761]
171. Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, et al. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. *Hum Mol Genet* 2002a;11:3039–3046. [PubMed: 12417525]

172. Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. *Ann Hum Genet* 2002b;66:111–124. [PubMed: 12174215]
173. Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, et al. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. *Journal of Lipid Research* 2008;49:369–375. [PubMed: 17986713]
174. Thompson A, Di AE, Sarwar N, Erqou S, Saleheen D, Dullaart RP, et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. *JAMA* 2008;299:2777–2788. [PubMed: 18560005]
175. Thompson JF, Wood LS, Pickering EH, Dechairo B, Hyde CL. High-density genotyping and functional SNP localization in the CETP gene. *Journal of Lipid Research* 2007;48:434–443. [PubMed: 17108362]
176. Tsujita Y, Nakamura Y, Zhang Q, Tamaki S, Nozaki A, Amamoto K, et al. The association between high-density lipoprotein cholesterol level and cholesteryl ester transfer protein TaqIB gene polymorphism is influenced by alcohol drinking in a population-based sample. *Atherosclerosis* 2007;191:199–205. [PubMed: 16674961]
177. Ukkola O, Garenc C, Perusse L, Bergeron J, Despres JP, Rao DC, et al. Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. *Atherosclerosis* 2001;158:199–206. [PubMed: 11500192]
178. van Aalst-Cohen ES, Jansen AC, Boekholdt SM, Tanck MW, Fontecha MR, Cheng S, et al. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. *Eur J Hum Genet* 2005;13:1137–1142. [PubMed: 16030523]
179. van der Vliet HN, Groenink Sammels M, Leegwater ACJ, Levels JHM, Reitsma PH, Boers W, et al. Apolipoprotein A-V: A novel apolipoprotein associated with an early phase of liver regeneration. *Journal of Biological Chemistry* 2001;276:44512–44520. [PubMed: 11577099]
180. Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, et al. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *American Journal of Epidemiology* 2006;164:342–348. [PubMed: 16760224]
181. Von Eckardstein A. Differential diagnosis of familial high density lipoprotein deficiency syndromes. *Atherosclerosis* 2006;186:231–239. [PubMed: 16343506]
182. Von Eckardstein A, Nofer JR, Assmann G. High Density Lipoproteins and Arteriosclerosis: Role of Cholesterol Efflux and Reverse Cholesterol Transport. *Arteriosclerosis, Thrombosis and Vascular Biology* 2001;21:13–27.
183. Wallace C, Newhouse SJ, Braund P, Zhang F, Tobin M, Falchi M, et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. *American Journal of Human Genetics* 2008;82:139–149. [PubMed: 18179892]
184. Wang X, Paigen B. Genetics of variation in HDL cholesterol in humans and mice. *Circ Res* 2005;96:27–42. [PubMed: 15637305]
185. Whitfield JB, O'Brien ME, Nightingale BN, Zhu G, Heath AC, Martin NG. ADH genotype does not modify the effects of alcohol on high-density lipoprotein. *Alcohol Clin Exp Res* 2003;27:509–514. [PubMed: 12658118]
186. Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, et al. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. *Am Heart J* 2005;150:243–250. [PubMed: 16086925]
187. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997;17:239–245.
188. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, Clarke R, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat Genet* 2008;40:161–169. [PubMed: 18193043]
189. Williams RR, Rao DC, Ellison RC, Arnett DK, Heiss G, Oberman A, et al. NHLBI family blood pressure program. Methodology and recruitment in the HyperGEN network. *Ann Epidemiol* 2000;10:389–400. [PubMed: 10964005]

190. Wilson PWF. High-density lipoprotein, low-density lipoprotein and coronary artery disease. *American Journal of Cardiology* 1990;66:7A–10A.
191. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease: The Framingham Offspring Study. *JAMA* 1994;272:1666–1671. [PubMed: 7966894]
192. Wittrop HH, Tybjaerg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease : A meta-analysis. *Circulation* 1999;99:2901–2907. [PubMed: 10359734]
193. Wu K, Bowman R, Welch AA, Luben RN, Wareham N, Khaw KT, et al. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. *Eur Heart J* 2007;28:2930–2936. [PubMed: 17982164]
194. Yamada Y, Ichihara S, Kato K, Yoshida T, Yokoi K, Matsuo H, et al. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. *J Med Genet* 2008;45:22–28. [PubMed: 17766366]
195. Yamada Y, Matsuo H, Warita S, Watanabe S, Kato K, Oguri M, et al. Prediction of genetic risk for dyslipidemia. *Genomics* 2007;90:551–558. [PubMed: 17919884]
196. Yamakawa-Kobayashi K, Yanagi H, Endo K, Arinami T, Hamaguchi H. Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children. *Human Genetics* 2003;113:311–315. [PubMed: 12884003]
197. Yamashita S, Sakai N, Hirano K, Ishigami M, Maruyama T, Nakajima N, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. *Front Biosci* 2001;6:D366–D387. [PubMed: 11229884]
198. Zaman MM, Ikemoto S, Yoshiike N, Date C, Yokoyama T, Tanaka H. Association of apolipoprotein genetic polymorphisms with plasma cholesterol in a Japanese rural population - The Shibata study. *Arteriosclerosis, Thrombosis and Vascular Biology* 1997;17:3495–3504.
199. Zhang K, Zhang S, Zheng K, He Y, Zhang L, Su Z, et al. Study on the association of lecithin cholesterol acyltransferase gene polymorphisms with the lipid metabolism in coronary atherosclerotic heart disease. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2003;20:135–137. [PubMed: 12673583]
200. Zhang K, Zhang S, Zheng K, Hou Y, Liao L, He Y, et al. Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease. *Biochemical and Biophysical Research Communications* 2004;318:4–10. [PubMed: 15110745]
201. Zhong SB, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. *Journal of Clinical Investigation* 1996;97:2917–2923. [PubMed: 8675707]
202. Zhu XY, Xu HW, Hou RY, Liu HF, Xiao B, Yang XS, et al. Lecithin-cholesterol acyltransferase gene 608C/T polymorphism associated with atherosclerotic cerebral infarction. *Zhonghua Yi Xue Yi Chuan Xue Za Zhi* 2006;23:419–422. [PubMed: 16883530]
203. Zietz B, Leonhardt K, Schäffler A. Kandidatengene des Diabetes mellitus Typ 2: Gibt es einen Gen-Dosiseffekt für Risikofaktoren sowie mikro- und makrovaskuläre Folgeerkrankungen? *Medizinische Klinik* 2006;101:605–616. [PubMed: 16896567]

Figure 1. Illustration of the major normal lipoprotein metabolic pathways

Refer to the text for detailed explanation. Blue arrows refer to points of action of the respective genes in blue. Red arrows refer to activating or inhibiting actions of certain apolipoproteins. Abbreviations: ABCA1, ATP binding cassette transporter 1; apo, apolipoprotein; CE, cholesterol ester; CETP, cholesteryl ester transfer protein; FFA, free fatty acid; HDL, high-density lipoprotein; IDL, intermediate-density lipoprotein; LCAT, lecithin:cholesteryl acyltransferase; LDL, low-density lipoprotein; LDLR, low-density lipoprotein-receptor; LIPC, hepatic lipase; LIPG, endothelial lipase; Lp(a), lipoprotein(a); LPL, lipoprotein lipase; SR-B1, scavenger receptor B1; TG, triglycerides; VLDL, very low-density lipoprotein. (Figure adapted from Kwan BCH, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. *J. Am. Soc. Nephrol.* 18:1246-1261, 2007.)

Figure 2. Correlation of SNPs in various HDLC candidate gene regions

The shading of the diamonds represents the category of the pairwise squared correlation coefficient r^2 between the two SNPs defined by the top left and the top right sides of the diamond. Specific value of r^2 are stated in the diamond. Data for each gene region are derived from HapMap (www.hapmap.org) using the genotyping results based on CEPH families (Utah residents with ancestry from northern and western Europe).

Figure 3. Mendelian Randomization Approach

Panel A shows some considerations concerning the sample size for Mendelian Randomization projects (for explanation see chapter 10 of the text). Panel B shows the results of a recent meta-analysis of the *TaqIB* polymorphism within the *CETP* gene and its association with HDLC levels as well as coronary disease (Thompson et al., 2008) (for details see chapter 10 of the text).

Table 1
Genetic variants within the *CETP* gene coding for the cholesteryl ester transfer protein and their association with HDLC concentrations.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs12149545	G-2708A	55550662	G>A	30	(McCaskey et al., 2007)	GP, CVD	W	2683 GP, 556 CVD	≈ +1.9 per copy	<0.001
			G>A	31	(Klerkx et al., 2003)	CVD	W	709	+1.5 / +3.5 (1/2 copies)	0.0016
rs3764261		55550825	G>T	28	(Pare et al., 2007)	CVD, Co	W	1442	n.a.	9×10 ⁻⁶
rs4783961	G-971A	55552395	G>A	49	(Klerkx et al., 2003)	CVD	W	709	+1.2 / +1.9 (1/2 copies)	0.09
rs1800775	C-629 A	55552737	C>A	48	(Borggreve et al., 2005)	P	W	7083	+2.7 / +5.4 (1/2 copies)	<0.001
			C>A	51	(Bernstein et al., 2003)	P	W	847 M, 873 F	+4.2 for homozygotes ^a	<0.002 ^a
			C>A	49	(Kathiresan et al., 2008a)	GP	W	5287	+3 / +5 (1/2 copies)	2×10 ⁻²⁹
			C>A	42-58	(Tai et al., 2003b)	GP	A	4050	+2.2 / +3.4 (1/2 copies) ^a	3.28×10 ^{-9a}
			C>A	48	(McCaskey et al., 2007)	GP, CVD	W	2683 GP, 556 CVD	≈ +2.7 per copy	<0.001
			C>A	40	(Blankenberg et al., 2004)	CVD Co	W	CVD: 1214 Co, 574	CVD: +2.0 / +3.5 (1/2 copies) Co: +3.3 / +6.1 (1/2 copies)	0.02 0.005
			C>A	44	(Klerkx et al., 2003)	CVD	W	709	+0.8 / +3.9 (1/2 copies)	<0.0001
			C>A	≈ 50	(Eiriksdottir et al., 2001)	MI, Co	W	309 MI, 757 Co	+1.9 / +6.1 (1/2 copies) ^a	<0.0001 ^a
			C>A	48	(Freeman et al., 2003)	CVD, Co	W	498 CVD, 1107 Co	+2.9 / +4.4 (1/2 copies) ^a	<0.001 ^a
rs708272 ^b	<i>Taq</i> 1B, <i>Taq</i> 1B	55553789	B1>B2	40-45	(Boekholdt et al., 2005)	M	-	13,677	+1.2 / +3.8 (1/2 copies)	<0.0001
	G+279A		B1>B2	n.a.	(Boekholdt et al., 2003)	M	-	>10,000	+4.6 for 2 copies	<0.00001
	(G=B1, A=B2)		B1>B2	42	(Borggreve et al., 2005)	P	W	7083	+2.7 / +5.0 (1/2 copies)	<0.001

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/ dL	P value
rs34145065 ^c			B1>B2	44	(Ordovas et al., 2000)	P	W	2916	$\approx +2.5$ / $+4.7$ (1/2 copies) ^a	<0.001 ^a
			n.a.	43W/26B	(Klos et al., 2006)	P	W/B	2056 W, 1943 B	n.a. / n.a.	<0.01 / <0.02
			G>A	W: 44	(Nettleton et al., 2007)	P	W	W: 8764	W: $+2.3$ / $+5.8$ (1/2 copies)	<0.001
				B: 27			B	B: 2695	B: $+3.8$ / $+9.8$ (1/2 copies)	<0.001
			B1>B2	41	(Sandhofer et al., 2008)	P	W	1503	$+2$ / $+5$ (1/2 copies)	<0.001
			B1>B2	33-43	(Tai et al., 2003b)	GP	A	4207	$+2.5$ / $+4.4$ (1/2 copies) ^d	1.25×10^{-10a}
			B1>B2	40	(Tsujita et al., 2007)	GP	A	1729	M: $+1.2$ / $+3.5$ (1/2 copies)	0.096
									F: $+1.9$ / $+6.2$ (1/2 copies)	<0.001
			B1>B2	42	(McCaskie et al., 2007)	GP, CVD	W	2683 GP, 556 CVD	$\approx +2.7$ per copy	<0.001
			B1>B2	42	(Whiting et al., 2005)	CVD, Co	W	2392 CVD, 827 Co	$+1.7$ / $+3.6$ (1/2 copies)	<0.001
rs289714			B1>B2	40	(Carlquist et al., 2003)	CVD	W	1464	$+2.1$ / $+3.0$ (1/2 copies)	0.003
			B1>B2	41	(Blankenberg et al., 2004)	CVD, Co	W	1200 CVD, 571 Co	$\approx +2.6$ / $+4.3$ (1/2 copies) ^a	<0.02 ^a
			B1>B2	44	(Freeman et al., 2003)	CVD, Co	W	499 CVD, 1105 Co	$\approx +2.1$ / $+3.6$ (1/2 copies) ^a	<0.001 ^a
	+784CCC>A	55554147-8	CCC>A	39	(Klerkx et al., 2003)	CVD	W	709	$+1.2$ / $+3.5$ (1/2 copies)	0.0009
			T>C	18	(Klos et al., 2006)	P	W	2056	M / F	0.018 / <0.001
	A373P	55572592	A>P G>C	5	(Agerholm-Larsen et al., 2000b)	P, CVD	W	8467 P, 1636 CVD	≈ -5.4 for heterozygotes	<0.001
			C>A	5	(Blankenberg et al., 2004)	CVD, Co	W	1039 CVD, 483 Co	≈ -3.6 for heterozygotes ^a	0.05 ^a

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/ dL	P value
rs5882 = rs61212082 ^b	Ile405Val	55573593	I>V		(Boekholdt et al., 2003)	M		>10,000	+1.9 for homozygotes	<0.00001
	A+16G/E×14		I>V	32	(Isaacs et al., 2007)	P	W	6421	M: +1.5 / +2.3 (1/2 copies)	0.002
	aa405		I>V	29	(Pallaud et al., 2001)	P	W	772 M, 780 F	F: +0.0 / +2.3 (1/2 copies) no association	0.007
	1394I>V		I>V	33	(Agerholm-Larsen et al., 2000a)	P	W	8889	M: ≈ +0.4 per copy	n.s.
			C>A	30	(Blankenberg et al., 2004)	CVD	W	CVD: 1208	F: ≈ +2.7 per copy CVD: +1.4 / +3.1 (1/2 copies)	<0.001 0.08
rs2303790 ^b			C>T	30	(Freeman et al., 2003)	CVD	W	Co:572	Co: +0.3 / +8.4 (1/2 copies)	0.003
						Co		CVD: 498	CVD: +1.2 / +3.5 (1/2 copies)	<0.05
						Co		Co: 1108	Co: +1.5 / +1.5 (1/2 copies)	<0.05
	D442G	55574793	D>G	3	(Zhong et al., 1996)	HeEx	A	3469	+4.9 for heterozygotes	<0.001
rs1800777	R451Q; G>A	55574820	R>Q	4	(Agerholm-Larsen et al., 2000b)	P, CVD	W	8467 P, 1636 CVD	≈ -5.4 for heterozygotes	<0.001
	G+82A/E×15		B1>B2	3	(Blankenberg et al., 2004)	CVD, Co	W	1071 CVD, 532 Co	-3.6 / -5.2 for heterozygotes	0.06 / 0.07

^a pooled estimates and p values.

^b Studies of this SNP with sample sizes <1000 are provided in the Supplementary Table.

^c rs number not fully clarified.

Abbreviations and explanations:

- Chrom. position: means chromosomal position according to NCBI Build 36 as included in Ensembl Release 49.
- Allele: means order of reference allele > risk allele; del, deletion; ins, insertion.

- MAF, minor allele frequency; Car., carriers; if MAF is not available, % Car. is provided.
- Study type: M, meta-analysis; P, population-based; GP, general population; Co, controls; CVD, cardiovascular disease; MI, myocardial infarction; NGT, normal glucose tolerance subjects; DM, diabetes mellitus; HoCo, hospital-based controls; HoSta, hospital staff; HBP, hypertensive patients; HeEx, health examination; Non-DM Co, nondiabetic control subjects; CorAng, coronary angiography; hyperCH, hypercholesterolemic patients.
- Ethnicity: W, Whites; B, Blacks; A, Asians; W-Bra, Caucasian-Brazilians; B-Bra, African-Brazilians; AA, African Americans; NHW, non-Hispanic Whites; H, Hispanics; UK, United Kingdom; Asian-Ind., Asian-Indians.
- HDLC, HDL cholesterol; M, males; F, females; sel., selected; n.s., not significant; n.a., not available.

Table 2
Genetic variants within the *LPL* gene coding for the lipoprotein lipase and their association with HDLC concentrations.^a

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs1801177	D9N; Asp9Asn	19849988	G>A	4% Car.	(Wittrop et al., 1999)	M	-	5067	-3.1 for heterozygotes	0.002
no rs #	Gly188Glu	19856022	Gly>Glu	1% Car.	(Wittrop et al., 1999)	M	-	10,434	-9.7 for heterozygotes	<0.001
rs268	N291S, Asn291Ser	19857809	A>G	5% Car.	(Wittrop et al., 1999)	M	-	14,912	-4.6 for heterozygotes	<0.001
rs320	HindIII; Int8	19863357	H+>H-	30	(Senti et al., 2001)	P	W	520	+5.5 in H-H- vs. H+H+	0.025
			H2>H1	26	(Holmer et al., 2000)	P	W	1361	M: +3.5 for heterozygotes	0.0018
									F 25-44yrs: no association	n.s.
									F 45-64yrs: +4.2 for heterozy.	0.0212
			H+>H-	32	(Corella et al., 2002)	GP	W	906	+1.9 for carriers	0.003
			T>G	17	(Ukkola et al., 2001)	GP	W	568	no association	n.s.
			H+>H-	42% Car.	(Radha et al., 2006)	NGT, DM	A	NGT: 550	NGT: +3.0 in carriers	<0.05
			+>-	27-31	(Ahn et al., 1993)	DM, Co	NHW, H	DM: 465 615 NHW, 579 H	DM: +1.0 in carriers higher values in carriers	<0.05 0.005
rs326		19863719	n.a.	44	(Klos et al., 2006)	P	B	1943	M / F	0.013 / 0.004
rs328 ^b	S447X ^c	19864004	S>X	20% Car.	(Wittrop et al., 1999)	M	-	4388	+1.5 for heterozygotes	<0.001
	1595CG		C>G	W: 10 B: 7	(Nettleton et al., 2007)	P	W	W: 8968 B: 2677	W: +2.8 / +4.0 (1/2 copies) B: +3.1 / +12.6 (1/2 copies)	<0.001 <0.001
			S>X	11	(Lee et al., 2004)	P	A	4058	+3.1 for carriers	<0.001

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/ dL	P value
			S>X	11	(Komurcu-Bayrak et al., 2007)	P	Turks	1586	M: no association	n.s.
			S>X	29	(Pallaud et al., 2001)	P	W	1552	F: +4.0 for carriers no association	<0.001 n.s.
			n.a.	n.a.	(Costanza et al., 2005)	P	W	1543	+ 2.7 for carriers	0.0017
			C>G	9	(Kathiresan et al., 2008a)	GP	W	5287	+3 / +5 (1/2 copies)	3×10 ⁻¹²
			S>X	10	(Talmud et al., 2002b)	GP	W	2773	no association	n.s.
rs13702		19868772	n.a.	50	(Klos et al., 2006)	P	B	1943	M / F	0.009 / 0.006

^a SNPs rs285 and rs10105606 never showed an association in any study but data on these studies are provided in the Supplementary Table.

^b Studies with sample sizes <1000 are provided in the Supplementary Table.

^c Position 474 instead of 447 according to NCBI database.

For abbreviations and explanations, see Table 1.

Table 3

Genetic variants within the *LIPC* gene coding for the hepatic lipase and their association with HDLC concentrations.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs1077834	T-710C	56510771	T>C	22	(Andersen et al., 2003)	P	W	9121	+3-4% per copy	<0.001
rs1800588 ^b	C-514T ^a	56510967	C>T	25	(Isaacs et al., 2004)	M	Various	>24,000	+1.5 / +3.5 (1/2 copies)	<0.001
	Pos. -480T ^d		C>T	W: 21 B: 53	(Nettleton et al., 2007)	P	W	W: 8897	W: +2.2 / +3.8 (1/2 copies)	<0.001
			C>T	21	(Isaacs et al., 2007)	P	W	6239	B: +1.6 / +4.0 (1/2 copies)	<0.001
			C>T	38	(Tai et al., 2003a)	P	A	2170	$\approx$ +1.3 / +4.3 (1/2 copies) ^d	<0.001 ^d
			C>T	21	(Kathiresan et al., 2008a)	GP	W	5287	+2.3 / +2.7 (1/2 copies)	0.001
			C>T	25	(Talmud et al., 2002b)	GP	W	2773	+1 / +4 (1/2 copies)	4×10 ⁻¹⁰
			C>T	24	(Whiting et al., 2005)	CVD, Co	W	3319 CVD, 1385 Co	+1.5 per copy	0.04
			C>T	51	(Yamada et al., 2007)	HoCo, P	A	5207	+1.0 / +3.8 (1/2 copies)	0.001
rs2070895	G-250A	56511231	G>A	22	(Andersen et al., 2003)	P	W	9121	$\approx$ +2.5 per copy	<0.001
	1b-280,HL1-280		n.a.	n.a.	(Costanza et al., 2005)	P	W	1543	$\approx$ +2.0-2.5 per copy	<0.001
			G>A	32	(de Andrade et al., 2004)	P	W	514	+3-4% per copy	<0.001
			G>A	23	(Grarup et al., 2008)	P	W	5585	+1.5 for carriers	0.020
			G>A	22	(Yamada et al., 2007)	P	W	8407	M: assoc., F: no assoc.	0.001 / n.s.
			G>A	51		HoCo, P	A	5213	+3.9 / +3.9 (1/2 copies)	8×10 ⁻¹⁰
			G>A	51		HoCo, P	A	5213	+3.9 / +3.9 (1/2 copies)	2×10 ⁻⁷
			G>A	51		HoCo, P	A	5213	$\approx$ +2.7 per copy	<0.001

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs12594375			G>A	39	(Ko et al., 2004)	HeEx	A	716	+2.1 for carriers	0.026
rs8023503		56519760	G>A	37	(Iijima et al., 2008)	GP	A	2970	n.a.	0.00003
no rs #	3b-279,HL3-279	56620996 ^c	n.a.	n.a.	(Costanza et al., 2005)	P	W	1543	+ 1.8 for carriers	0.024
rs3829462	+1075C	56640371	A>C	5	(Fang et al., 2002)	HoSta	A	823	+8.0 for heterozygotes	<0.05

^aC-514T and -480T are the same polymorphisms (depending on the nucleotide taking as the transcription start site).

^bStudies with sample sizes <1000 are provided in the Supplementary Table.

^cIt is also possible that the known SNP 3b-280 is meant (rs12909325; chrom. position 56620995).

^dpooled estimates and p values.

^efor abbreviations and explanations, see Table 1.

Table 4
Genetic variants within the *LIPG* gene coding for the endothelial lipase and their association with HDLC concentrations.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs3813082	-384A>C	45342041	A>C	12	(Hutter et al., 2006)	Co	A	541	+1.3 / +10.2 (1/2 copies)	0.021
			A>C	12	(Yamakawa-Kobayashi et al., 2003)	Kids	A	340	+0.7 / +9.8 (1/2 copies)	0.0086
rs2000813	584 C/T	45347862	T>I	32	(Paradis et al., 2003)	GP	W	495	M: +1.2 / +2.7 (1/2 copies) F: -0.4 / +1.9 (1/2 copies)	0.82
	T1111		C>T	24	(Hutter et al., 2006)	Co	A	541	+0.5 / +6.1 (1/2 copies)	0.048
			C>T	18 / 30	(Tang et al., 2008)	CVD, Co	A	265 CVD, 265 Co	≈ +3.7 in carriers ^a	<0.02 ^a
			C>T	24	(Yamakawa-Kobayashi et al., 2003)	Kids	A	340	-0.6 / +2.6 (1/2 copies)	n.s.
			C>T	29	(Ma et al., 2003)	CVD	90% W	372	+1.6 / +6.0 (1/2 copies)	0.035
rs2276269	C+42T/ln5	45356000	C>T	44	(Mank-Seymour et al., 2004)	HDL sel. ^b	W	594	decreases HDLC	0.007
rs6507931	T+2864C/ln8	45367006	T>C	42	(Mank-Seymour et al., 2004)	HDL sel. ^b	W	594	decreases HDLC	0.004
rs3744841	2237G>A	45371372	G>A	36	(Yamakawa-Kobayashi et al., 2003)	Kids	A	340	-4.0 / -4.3 (1/2 copies)	0.011

^a pooled estimates and p values.

^b Selected according to HDLC levels: high HDLC group with values >60 mg/dL (n=355) and low HDLC group with values <35 mg/dL (n=239).

For abbreviations and explanations, see Table 1.

Table 5

Genetic variants within the *LCAT* gene coding for the lecithin:cholesterol acyltransferase and their association with HDLC concentrations.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
no rs #	Gly230Arg	66531921	Gly>Arg	5% Car. ^a	(Miettinen et al., 1998)	see ^a	W	156 low HDLC, 160 high HDLC	variant only in low HDLC group	
rs4986970	Ser208Thr	66533821	S>T	3	(Talmud et al., 2002b)	GP	W	2773	no association	n.s.
	Ser208Thr		S>T	6% Car.	(Boekholdt et al., 2006)	CVD	W	546	no association	n.s.
rs5922	608C/T	66533918	C>T	n.a.	(Zhang et al., 2003)	CVD, Co	A	CVD: 203	increase in HDL	0.015
			C>T	14% Car.	(Zhu et al., 2006)	Stroke, Co	A	Co: 209 150 stroke, 122 Co	no association lower HDLC in heterozyg.	n.s. <0.05
no rs #	P143L +511C>T	66534134	C>T	6% Car.	(Zhang et al., 2004)	CVD, Co	A	190 CVD, 209 Co	association with low HDLC	<0.01
rs2292318		66543207	G>A	12	(Pare et al., 2007)	CVD, Co	W	1442	increases HDLC	2×10^{-5}

^a 5% carriers in 156 persons with low HDL (8-27 mg/dL) vs. 0% carriers in 160 persons with high HDL (73-139 mg/dL) selected from a large population study.

For abbreviations and explanations, see Table 1.

Table 6

Genetic variants within the *SCARB1* (*SR-BI*) gene coding for the scavenger receptor class B type 1 and their association with HDLC concentrations.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs5888	A350A	123850701	C>T	48	(Osgood et al., 2003)	P	W	M: 1177	M: +1.2 / +2.3 (1/2 copies)	n.s.
	(exon8 C-T)		C>T	44	(Morabia et al., 2004)	P	W	F: 1239	F: 0.0 / +1.2 (1/2 copies)	n.s.
	C1050T		n.a.	n.a.	(Costanza et al., 2005)	P	W	M: 865	M: +1.9 / 2.7 (1/2 copies)	0.0062
			n.a.	n.a.	(Roberts et al., 2007)	P	W	F: 891	F: +0.4 / +0.8 (1/2 copies)	n.s.
			C>T	41	(Roberts et al., 2007)	Families	Amish	1543	- 5.1 for carriers	n.s.
			C>T	49	(Boekholdt et al., 2006)	CVD	W	M: 428	M: no association	n.s.
								F: 491	F: $\approx +4$ / $+3$ (1/2 copies)	0.04
								546	+2.3 / +1.9 (1/2 copies)	0.03
rs5891		123865495	G>A	3	(Roberts et al., 2007)	Families	Amish	M: 428	M: no association	n.s.
								F: 491	F: $\approx +9$ / $+10$ (1/2 copies)	<0.001
rs4238001	Ex.1(G>A)	123914216	G>A	12	(Osgood et al., 2003)	P	W	2465	+0.4 for carriers	n.s.
no rs #	11-bp del ^d	123914499-509	ins>del ^d	4% Car.	(Hsu et al., 2003)	HeEx	A	690	+6.0 for deletion carriers	0.035
no rs #	C-142T	123914515	C>T	14	(Hsu et al., 2003)	HeEx	A	664	+1 / -1 (1/2 copies)	n.s.

^d Eleven base pair deletion ranging from position -140 to -150. -140 to -150del mutation identified in the transcription factor binding region of the *SCARB1* gene.

For abbreviations and explanations, see Table 1.

Table 7
Genetic variants within the *ABCA1* gene coding for the ATP binding cassette transporter A1 and their association with HDLC concentrations.^a

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs2246298	C(-297)T	106730554	C>T	25	(Shioji et al., 2004b)	GP	A	1625	n.a.	0.0455
rs1800976	G(-273)C	106730530	G>C	40	(Shioji et al., 2004b)	GP	A	GP: 1626	+1.9 / +2.7 (1/2 copies)	0.026
						HBP	A	HBP: 735	+1.9 / +5.0 (1/2 copies)	0.026
rs1800977	C69T; C-14T	106730271	C>T	36	(Porchay et al., 2006)	GP	W	5040	no association	n.s.
			C>T	38	(Hodoglugil et al., 2005)	GP (no DM)	Turks	2332	M: +0.7 / +1.9 (1/2 copies) F: -0.3 / 0.0 (1/2 copies)	<0.02 n.s.
rs1800978	G378C	106705799	G>C	13	(Porchay et al., 2006)	GP	W	5040	-1.2 / -2.7 (1/2 copies)	0.03
rs3890182		106687476	G>A	13	(Kathiresan et al., 2008a)	GP	W	5287	-1 / -3 (1/2 copies)	0.003
rs2275542	IMS-JST071749	106684901	n.a.	n.a.	(Shioji et al., 2004b)	GP	A	<1880	n.a.	0.006
rs2515602		106639989	n.a.	27	(Klos et al., 2006)	P	B	1943	M / F	0.034 / <0.001
rs2853578	G596A	106633129	G>A	28	(Whiting et al., 2005)	CVD, Co	W	2468 CVD, 834 Co	-0.2 / +2.8 (1/2 copies)	0.02
rs2066718	V771M	106629076	G>A	3	(Frikke-Schmidt et al., 2004)	P	W	9123	M: trend to higher levels	0.12
	2310G>A								F: higher levels in carriers	0.02
	G2706A		V>M	5	(Hodoglugil et al., 2005)	GP (no DM)	Turks	2458	M: +2.0 for heterozygotes	<0.01

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs2066715	V825I 2472G>A G2868A	106627854	V>M	3	(Clee et al., 2001)	CVD	W	635	F: +1.9 for heterozygotes no association	n.s. n.s.
					(Frikke-Schmidt et al., 2004)	P	W	9123	M: no association	n.s.
					(Hodoglugil et al., 2005)	GP (no DM)	Turks	2105	F: $\approx$ +3.1 in carriers no association	0.0005 n.s.
					(Clee et al., 2001)	CVD	W	682	no association	n.s.
rs4149313	I883M 2648A>G	106626574	A>G	12	(Frikke-Schmidt et al., 2004)	P	W	9123	M: no association	n.s.
					(Hodoglugil et al., 2005)	GP (no DM)	Turks	2532	F: increase in hetercygotes no association	0.05 n.s.
rs33918808	E1172D 3515G>C	106619453	G>C	3	(Frikke-Schmidt et al., 2004)	P	W	9123	M: no association	n.s.
					(Hodoglugil et al., 2005)	GP (no DM)	Turks	2238	F: higher levels in carriers no association	0.05 n.s.
					(Clee et al., 2001)	CVD	W	644	no association	n.s.
no rs #	32b.+30, ABC32	106606881	n.a.	n.a.	(Costanza et al., 2005)	P	W	1543	- 2.2 for carriers	0.0040
rs2230808	R1587K 4759G>A	106602625	G>A	24	(Frikke-Schmidt et al., 2004)	P	W	9123	M: -1.5 for heterozygotes F: -2.7 for heterozygotes no association	0.008 0.02 n.s.
					(Hodoglugil et al., 2005)	GP (no DM)	Turks	2288		
					(Clee et al., 2001)	CVD	W	779	-1.5 for carriers	0.03

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs41474449	50b.3038, ABC50	106583518-20	del/ins	n.a.	(Costanza et al., 2005)	P	W	1543	+ 1.6 for carriers	0.043

^a SNPs rs2422493, rs2740483, rs1799777 and rs2230806 never showed an association in any study but data on these studies are provided in the Supplementary Table.
For abbreviations and explanations, see Table 1.

Genetic variants within the genes *APOA1*, *APOC3* and *APOA5* coding for apolipoprotein A-I, C-III and A-V, respectively and their associations with HDLC concentrations.^a

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/ dL	P value
APOAI										
rs5070	T84C (1280)	116213230	T>C	W:33/B:47	(Brown et al., 2006)	P	Multi	3831	no association	n.s.
	(HaeIII)		T>C	23	(Shioji et al., 2004a)	GP	A	1637	+1.9 / +5.4 (1/2 copies)	0.0005
rs5069	MspI RFLP	116213464	T>C	W: 3	(Brown et al., 2006)	P	W, B	3831	W: M / F	0.0001 / 0.027
	C-151T		+>-	B: 31	(Kamboh et al., 1996)	GP	NHW	M: 248	B: M / F	n.s. / 0.022
				3				M: -3.0 in carriers	n.s.	
	+83bp; +83 C/T		+>-	40	(Kamboh et al., 1999)	GP	A	F: 280	F: +7.5 in carriers	0.009
						M: 490	M: -2.3 / -0.9 (1/2 copies)	n.s.		
1046 (C>T)			M1>M2	44	(Zaman et al., 1997)	Co	A	F: 291	F: +0.1 / -0.9 (1/2 copies)	n.s.
APOC3				5	(Larson et al., 2002)	Co	W	730	≈ +2.0 for carriers	n.s.
rs2854117	-482C>T (9154)	116205352	G>A	W: 73	(Brown et al., 2006)	P	Multi	3831	W: M / F	n.s. / n.s.
			C>T	B: 33	(Pallaud et al., 2001)	P	W	772 M, 780 F	B: M / F	n.s. / 0.014
				27					no association	n.s.
						T>C	27	(Qi et al., 2007)	GP (DM)	W
rs2854116	C-455T, 9127	116205379	A>G	W: 62	(Brown et al., 2006)	P	Multi	3831	W: M / F	n.s. / n.s.
			B: 30					B: M / F	n.s. / 0.045	

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs618354 ^C	PvuII	116205987	T>C	41	(Lahiry et al., 2007)	P	Inuits	1308	-3.1 / -5.4 (1/2 copies)	<0.05
			T>C	38	(Qi et al., 2007)	GP (DM)	W	846	+0.2 / -1.7 (1/2 copies)	n.s.
rs5128	+3175 SstI RFLP	116208850	1>2	49	(Kamboh et al., 1999)	GP	A	M: 478 F: 291	M: -0.9 / -1.3 (1/2 copies) F: +0.1 / -4.2 (1/2 copies)	n.s. 0.029
			C>G	9	(Pallaud et al., 2001)	P	W	772 M, 780 F	no association	n.s.
3'-UTR/Sac I	3238C>G		S1>S2	9	(Russo et al., 2001)	P	W	M: 1219	M: -1.8 in carriers	0.04
			->+	9	(Hegele et al., 1995)	P	Hutteries	F: 1266 713	F: +0.4 in carriers -5.0 for heterozygotes	n.s. 0.0014
APOA5			S1>S2	7	(Corella et al., 2002)	GP	W	906	+1.9 for carriers	0.079
			S1>S2	35	(Arai et al., 2005)	GP	A	852	-0.8 / -1.5 (1/2 copies)	0.41
			C>G	10	(Qi et al., 2007)	GP (DM)	W	881	+2.4 / -2.0 (1/2 copies)	n.s.
			S1>S2	36	(Zaman et al., 1997)	Co	A	1328	+0.2 / +1.5 (1/2 copies)	n.s.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/ dL	P value
rs651821	-3A>G	116167789	T>C	34	(Yamada et al., 2007)	HoCo, P	Asian-Ind. A	Asian-Ind.: 553 5212	0.0 / -3.1 (1/2 copies) ≈ -3.3 per copy	n.s. <0.001
					(Klos et al., 2006)	P	W	2056	M / F	0.30 / 0.26
					(Lai et al., 2003)	GP	Chinese	Chinese: 2711	-2.3 / -5.8 (1/2 copies)	<0.0001
							Malays	Malays: 707	-0.8 / -7.3 (1/2 copies)	<0.0001
			T>C	34	(Yamada et al., 2007)	HoCo, P	Asian-Ind.	Asian-Ind.: 553	-0.4 / -6.2 (1/2 copies)	0.0913
					(Yamada et al., 2008)	HoCo	A	5207	≈ -2.7 per copy	<0.001
							A	2417	-3.9 / -7.0 (1/2 copies)	<0.001
rs3135506 ^b	S19W 56C>G +170	116167617	S>W C>G C>G	6 6 6-7	(Talmud et al., 2002a)	P	UK	1660	-1.9 / +1.2 (1/2 copies)	0.02
					(Lai et al., 2004)	P	W	2347	-2.0 for carriers	0.008
					(Grallert et al., 2007)	P	W	KORA:1116	KORA: -1.5 per copy	n.s
								SAPHIR: 1630	SAPHIR: -2.3 per copy	0.026
rs2072560	SNP2 IVS3+476G>A +751C/T	116167036	G>A C>T	16-21 12% Car.	(Lai et al., 2003)	GP	Chinese	Chinese: 2711	-1.9 / -3.9 (1/2 copies)	0.0003
							Malays	Malays: 707	-0.4 / -9.3 (1/2 copies)	0.0004
					(Qi et al., 2007)	GP (DM)	Asian-Ind.	Asian-Ind.: 553	+0.4 / -3.5 (1/2 copies)	n.s.
							W	884	-0.8 for carriers	n.s.
rs3135507	Val153Met V153M	116166698	V>M	7% Car.	(Hubacek et al., 2005)	P	W	2557	M: -0.8 for carriers F: -3.5 for carriers	n.s. <0.01
rs2075291	+553	116166602	G>T	7	(Yamada et al., 2007)	HoCo, P	A	5206	≈ -4.6 per copy	<0.001

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/ dL	P value
rs2266788	Gly185Cys	116165896	G>T	8	(Yamada et al., 2008)	HoCo	A	2417	-5.0 / -11.2 (1/2 copies)	<0.001
			G>T	30	(Hsu et al., 2006)	HeEx	A	677	-2.0 for carriers	n.s.
rs2266788	1259T>C +1891A>G	116165896	T>C	18-23	(Lai et al., 2003)	GP	Chinese	Chinese: 2711	-2.3 / -3.1 (1/2 copies)	<0.0001
							Malays	Malays: 707	-0.4 / -6.6 (1/2 copies)	0.008
							Asian-Ind.	Asian-Ind.: 553	-0.4 / -2.3 (1/2 copies)	n.s.
			A>G	14% Car.	(Qi et al., 2007)	GP (DM)	W	864	-0.7 for carriers	n.s.

^a SNPs rs670 (*APOA1*), rs4520 (*APOC3*), rs34635405 (*APOC3*), rs2266789 (*APOA5*), rs10750097 (*APOA5*) never showed an association in any study but data on these studies are provided in the Supplementary Table.

^b Studies of this SNP with sample sizes <1000 are provided in the Supplementary Table.

^c rs number not fully clarified.

For abbreviations and explanations, see Table 1.

Table 9
Genetic variants within the genes *GHRL*, *LDLR* and *PON1* coding for ghrelin, LDL-receptor and paraoxonase 1, respectively and their associations with HDLC concentrations.^a

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
<i>GHRL</i>										
rs3755777	-1500C>G	10308364	C>G	49	(Choi et al., 2006)	Non-DM Co	A	641	-2 for carriers	0.0020
rs26311	-1062G>C	10307926	A>G	12	(Martin et al., 2008)	GP	Canadian	1464	no association	n.s.
			G>C	37	(Choi et al., 2006)	Non-DM Co	A	640	-4 for carriers	<0.0001
rs26312	-994C>T	10307858	C>T	39	(Choi et al., 2006)	Non-DM Co	A	639	-3 for carriers	0.0004
rs26802		10307365	T>G	30	(Martin et al., 2008)	GP	Canadian	1464	no association	n.s.
rs696217	+408C>A	10306457	C>A	18	(Choi et al., 2006)	Non-DM Co	A	636	-2 for carriers	0.0042
	Leu72Met		Leu>Met	7	(Hubacek et al., 2007)	P	W	1189 M, 1364 F	-2.3 for carriers	0.01
rs2075356		10303809	T>C	11	(Martin et al., 2008)	GP	Canadian	1464	no association	n.s.
rs4684677		10303453	T>A	6	(Martin et al., 2008)	GP	Canadian	1464	no association	0.09
rs35684		10301686	A>G	27	(Martin et al., 2008)	GP	Canadian	1464	no association	n.s.
<i>LDLR</i>										
rs2228671	Exon 2	11071912	n.a.	n.a.	(Costanza et al., 2005)	P	W	1543	+3.8 for carriers	0.0056

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDL C in mg/dL	P value
rs688 = rs57911429	1866C>T Asn591Asn	11088602	C>T	12	(Yamada et al., 2008)	HoCo	A	2417	+1.5 / +8.5 (1/2 copies)	0.0155
	Exon 12/HincII		->+	39	(Hegele et al., 1995)	P	Hutteries	713	-2.3 / -4.3 (1/2 copies)	0.047
rs5925 = rs57369606	2052T>C Val653Val	11091881	T>C	17	(Yamada et al., 2008)	HoCo	A	2417	+1.2 / +5.4 (1/2 copies)	0.043
<i>PONI</i>										
rs662 = rs60480675	Q192R	94775382	A>G	30	(Srinivasan et al., 2004)	P	W	W: 1232	W: +0.1 / +2.3 (1/2 copies)	0.041
	Gln192Arg			67			B	B: 554	B: -5.4 / -6.7 (1/2 copies)	0.008
				31	(Manresa et al., 2006)	P	W	1364	-0.6 for carriers	n.s.
				31	(Senti et al., 2002)	P	W	M: 724	M: 0.0 / -0.6 (1/2 copies)	n.s.
								F: 656	F: +0.6 / -1.6 (1/2 copies)	n.s.
				29	(Hegele et al., 1995)	P	Hutteries	738	-3.1 / -3.1 (1/2 copies)	0.001
				32	(van Aalst-Cohen et al., 2005)	hyperCH	W	1002	0.0 / -0.8 (1/2 copies)	n.s.
				36	(Rios et al., 2007)	CVD, Co	W-Bra	M: 261	M: +1.5 / +2.7 (1/2 copies)	0.035
								F: 176	F: -0.4 / +3.1 (1/2 copies)	n.s.
				46			B-Bra	M: 155	M: -0.4 / +1.5 (1/2 copies)	n.s.
								F: 120	F: +0.4 / +1.2 (1/2 copies)	n.s.
				27	(Blatter Garin et al., 2006)	CVD, Co	W	CVD: 710	CVD: -1.2 / -3.5 (1/2 copies)	n.s.
				33				Co: 199	Co: +0.8 / +1.2 (1/2 copies)	n.s.

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
rs3202100 = Met55Leu		94784020	Met>Leu	35	(van Aalst-Cohen et al., 2005)	hyperCH	W	1002	-0.4 / 0.0 (1/2 copies)	n.s.
rs17434839=rs57937067			L>M	40	(Blatter Garin et al., 2006)	CVD, Co	W	CVD: 710	CVD: 0.0 / 0.0 (1/2 copies)	n.s.
				34				Co: 199	Co: +0.4 / +3.9 (1/2 copies)	n.s.
			Leu>Met	43	(Rios et al., 2007)	CVD, Co	W-Bra	437	no association	n.s.
				34			B-Bra	275		
rs705379	C-107T	94791831	T>C	48	(Blatter Garin et al., 2006)	CVD, Co	W	CVD: 710	CVD: -3.1 / -2.3 (1/2 copies)	0.006
				47				Co: 199	Co: 0.0 / +8.1 (1/2 copies)	0.001

^a SNPs rs1433099 and rs2738466 of *LDLR* never showed an association in any study but data on these studies are provided in the Supplementary Table. For abbreviations and explanations, see Table 1.

Table 10
Association of the *APOE* polymorphism coding for apolipoprotein E with HDLC concentrations.^a

Study name	Sample size	Influence of E2 on HDL	Influence of E4 on HDL	P value ^b
EPIC Norfolk Study (Wu et al., 2007)	22,915	↑	↓	<0.001
ARIC Study (Volcik et al., 2006)	9304 Whites	↑	↓	<0.05
	3187 African Americans	↑	↓	<0.05
Copenhagen City Heart Study (Frikke-Schmidt et al., 2000)	5025 women	↑	↓	<0.001
	4035 men	↔	↓	n.s. / 0.001
Rotterdam Study (Slooter et al., 2001)	5401	↑	↓	<0.0005
Strong Heart Study (Kataoka et al., 1996)	1296 nondiabetic women	↑	↓	0.007
	1040 nondiabetic men	↔	↔	n.s.
	1322 diabetic women	↑	↓	0.040
	752 diabetic men	↔	↔	n.s.
Suita Study (Katsuya et al., 2002)	3997	n.d.	↓	0.003
Framingham Offspring Study (Wilson et al., 1994)	916 women	OR for HDL<35 = 0.80	OR for HDL<35 = 1.15	n.s.
	1034 men	OR for HDL<35 = 1.36	OR for HDL<35 = 1.37	0.11 / 0.06
Cardiovascular Risk in Young Finns Study (Gronroos et al., 2007)	1736	↑	↓	0.04
(Costanza et al., 2005)	1543	↑	n.d.	0.00078
Bogalusa Heart Study (Srinivasan et al., 1999)	1477	↑	↔	<0.05 / n.s.

^aDue to the high number of studies investigating the *APOE* polymorphism, only large (n>1000) population-based studies are provided in this Table.

^bP value from ANOVA comparing the major genotype groups.

n.s., not significant; n.d., not done.

Table 11

Genetic variants in genes rarely investigated, which showed significant association with HDLC levels in at least one large study (n>1000).

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
<i>ALDH2 = aldehyde dehydrogenase 2</i>										
rs671	Glu487Lys	110726149	Glu>Lys	30	(Takagi et al., 2001)	P	A	M: 1919	M: -2.3 / -8.5 (1/2 copies)	<0.0001
				28				F: 2138	F: -1.9 / -1.9 (1/2 copies)	0.0254
	ALDH2 *1-*2		1>2	31	(Nakamura et al., 2002)	GP	A	M: 826	M: -1.8 / -3.5 (1/2 copies)	n.s.
				28				F: 1295	F: -1.2 / -0.2 (1/2 copies)	n.s.
<i>CD36 = CD36 antigen</i>										
rs10499859 ^d		80096746	A>G	33	(Love-Gregory et al., 2008)	HyperGen ^b	AA	2020	+2.5 per copy	2.8×10 ⁻⁴
<i>DGATI = acyl CoA:diacylglycerol acyltransferase 1</i>										
rs7003945	C79T	145521273	T>C	43	(Ludwig et al., 2002)	P	W	1322	-1.8 / -1.4 (1/2 copies)	0.019
<i>EDN1 = endothelin-1</i>										
rs5370		12404241	G>T	21	(Pare et al., 2007)	CVD, Co	W	1442	decreases HDLC	1×10 ⁻⁵
<i>MCC = mast cell chymase</i>										
rs1800875	G3255A	24049178	G>A	20	(Fukuda et al., 2002)	P	A	1046	+2.5 / +1.8 (1/2 copies)	0.038

rs number	Alias	Chrom. position	Allele	MAF	Study	Study type	Ethnicity	Sample size	Change in HDLC in mg/dL	P value
<i>NR1H3 = liver X receptor alpha</i>										
rs11039155	-6G>A	47237338	G>A	11	(Legry et al., 2008)	P	W	2290	+2.1 for carriers	0.007
<i>PPAR-α = peroxisome proliferator activated receptor alpha</i>										
rs1800206	L162V	44992938	L>V	4	(Manresa et al., 2006)	P	W	1204	-4.0 for carriers	<0.05
<i>PPAR-γ2 = peroxisome proliferator activated receptor gamma 2</i>										
rs1805192	Pro12Ala	12396238	Pro>Ala	5	(Tai et al., 2004)	P	A	4038	+1.6 for carriers	0.028
rs3856806	C1431T	12450557	C>T	23	(Tai et al., 2004)	P	A	4038	no association	n.s.
<i>PRKAA2 = AMP-kinase α2 subunit</i>										
rs2796498	1 - 2	56916574	1>2	46	(Spencer-Jones et al., 2006)	GP	W	2275	-1.5 / -2.3 (1/2 copies)	0.01
<i>ZNF202 = Zinc Finger P protein 202</i>										
rs3183878	c.*2T>G Exon10	123101913	T>G	39	(Stene et al., 2006)	P	W	F: 5039 M: 4064	F: no association M: -1.9 for homozygous Car.	n.s. 0.05

^a 15 additional SNPs in *CD36* were significantly associated with HDLC with varying direction of the effects on HDLC (increase or decrease).

^bThe HyperGen (Hypertension Genetic Epidemiology Network) Study recruited hypertensive siblings diagnosed before age 60 from sibships with two or more affected persons, normotensive offsprings and random controls. Details on the study are provided in reference (Williams et al., 2000).

For abbreviations and explanations, see Table 1.

Table 12

SNPs associated with HDLC concentrations in GWA studies. For each study and each gene, the SNP with the best p value is shown.

Gene	Chr.	Chrom. position	rs number	MAF	Study	Results from initial GWAS scan			Results GWAS scan + replication studies	
						Sample size	Change in HDLC	P value	Sample size	P value
<i>CETP</i>	16	55562980	rs1532624	43	(Aulchenko et al., 2008)	19,674	8.24 (z-sc) ^b	9.4×10 ⁻⁹⁴		
		55550825	rs3764261	31	(Willer et al., 2008)	8656	2.42 mg/dL	2.8×10 ⁻¹⁹	8656+8072	2.3×10 ⁻⁵⁷
		55550825	rs3764261	31	(Cashman et al., 2008)	6382	4.0 mg/dL	1.0×10 ⁻⁴¹		
		55552737	rs1800775	49	(Kathiresan et al., 2008b)	2758	2.6 mg/dL	3×10 ⁻¹³	2758+18,554	1×10 ⁻⁷³
		55552737	rs1800775	47	(Heid et al., 2008)	1643	3.99 mg/dL	6.05×10 ⁻¹⁵		
		55542640	rs9989419	39	(Heid et al., 2008)	1643	-2.68 mg/dL	1.86×10 ⁻⁶	8216	8.50×10 ⁻²⁷
		55542640	rs9989419	40	(Wallace et al., 2008)	1636		5.99×10 ⁻³	1636+2631	1.03×10 ⁻¹⁰
<i>LPL</i>	8	55562390	rs7205804	37-50	(Kooner et al., 2008)				10,536	4.7×10 ⁻⁴⁷
		19909455	rs2083637	26	(Aulchenko et al., 2008)	17,922	4.14 (z-sc) ^b	5.5×10 ⁻¹⁸		
		19891970	rs10503669	10	(Willer et al., 2008)	8656		3.2×10 ⁻¹⁰	8656+11,431	4.1×10 ⁻¹⁹
		19864685	rs331	28	(Cashman et al., 2008)	6382	1.5 mg/dL	9.1×10 ⁻⁷		
		19864004	rs328	9	(Kathiresan et al., 2008b)	2758	2.21 mg/dL	3×10 ⁻⁴	2758+18,554	9×10 ⁻²³
		19876926	rs17482753	10	(Heid et al., 2008)	1643	3.70 mg/dL	2.71×10 ⁻⁵	8180	2.82×10 ⁻¹¹
		19896590	rs17411031	27	(Wallace et al., 2008)	1636		2.12×10 ⁻⁵	1636+2631	1.28×10 ⁻¹⁰
<i>LIPC</i>	15	19863719	rs326	22-30	(Kooner et al., 2008)				10,536	1.8×10 ⁻⁸
		56470658	rs1532085	41	(Aulchenko et al., 2008)	19,736	5.03 (z-sc) ^b	9.7×10 ⁻³⁶		

Gene	Chr.	Chrom. position	rs number	MAF	Study	Results from initial GWAS scan			Results GWAS scan + replication studies	
						Sample size	Change in HDL C	P value	Sample size	P value
<i>LIPG</i>	18	56461987	rs4775041	33	(Willer et al., 2008)	8656		2.8×10^{-9}	8656+11,426	3.2×10^{-20}
		56470658	rs1532085	37	(Cashman et al., 2008)	6382	1.8 mg/dL	1.3×10^{-10}		
		56510967	rs1800588	21	(Kathiresan et al., 2008b)	2758	1.95 mg/dL	3×10^{-5}	2758+18,554	2×10^{-32}
		56514617	rs261332	21	(Wallace et al., 2008)	1636		7.0×10^{-3}	1636+2631	5.02×10^{-7}
		56530023	rs11858164	27-55	(Kooner et al., 2008)				10,536	7.0×10^{-8}
<i>ABCA1</i>	9	45421212	rs4939883	17	(Aulchenko et al., 2008)	16,258	-3.98 (z-sc) ^b	1.6×10^{-11}		
		45435666	rs2156552	16	(Willer et al., 2008)	8656		8.4×10^{-7}	8656+11,437	6.4×10^{-12}
		45435666	rs2156552	18	(Kathiresan et al., 2008b)	2758	-1.17 mg/dL	0.02	2758+18,554	2×10^{-7}
		45413088	rs7240405	17	(Heid et al., 2008)	1643	-2.77 mg/dL	3.19×10^{-4}	8213	4.67×10^{-10}
<i>ABCA1</i>	9	106696891	rs3905000	14	(Aulchenko et al., 2008)	17,913	-4.37 (z-sc) ^b	8.6×10^{-13}		
		106687041	rs4149268	36	(Willer et al., 2008)	8656		3.3×10^{-7}	8656+11,327	1.2×10^{-10}
		106687476	rs3890182	13	(Kathiresan et al., 2008b)	2758	-2.21 mg/dL	3×10^{-5}	2758+18,554	3×10^{-10}
		106687476	rs3890182	12	(Wallace et al., 2008)	1636		3.8×10^{-2}	1636+2631	2.09×10^{-6}
<i>LCAT</i>	16	106660656	rs9282541	0-9	(Kooner et al., 2008)				10,536	4.8×10^{-8}
		66582496	rs255052	17	(Willer et al., 2008)	8656		1.5×10^{-6}	8656+4534	1.2×10^{-7}

Gene	Chr.	Chrom. position	rs number	MAF	Study	Results from initial GWAS scan			Results GWAS scan + replication studies	
						Sample size	Change in HDL.C	P value	Sample size	P value
<i>APOA1C3A4A5</i>	11	116233840	rs12225230	18	(Cashman et al., 2008)	6382	1.5 mg/dL	5.3×10^{-5}		
		116124283	rs28927680	7	(Kathiresan et al., 2008b)	2758	-0.78 mg/dL	0.31	2758+18,554	2×10^{-5}
<i>APOB</i>	2	21059688	rs6754295	25	(Aulchenko et al., 2008)	17,915	2.63 (z-sc) ^b	4.4×10^{-8}		
<i>CTCF-PRMT8</i>	16	66459571	rs2271293	13	(Aulchenko et al., 2008)	17,910	4.99 (z-sc) ^b	8.3×10^{-16}		
<i>MADD-FOLH1</i>	11	48475469	rs7395662	39	(Aulchenko et al., 2008)	17,917	2.82 (z-sc) ^b	6.0×10^{-11}		
<i>GALNT2</i>	1	228361539	rs2144300	40	(Willer et al., 2008)	8656		6.6×10^{-7}	8656+11,406	2.6×10^{-14}
		228362314	rs4846914	40	(Kathiresan et al., 2008b)	2758	-1.30 mg/dL	3×10^{-4}	2758+18,554	2×10^{-13}
<i>MVK/MMAB</i>	12	108379551	rs2338104	45	(Willer et al., 2008)	8656		1.9×10^{-6}	8656+11,399	3.4×10^{-8}
<i>CLPTM1</i>	19	50169221	rs16979595	16	(Wallace et al., 2008)	1636		6.11×10^{-3}	1636+2631	5.79×10^{-6}
<i>GRIN3A</i>	9	103402758	rs1323432	12	(Willer et al., 2008)	8656	1.93 mg/dL	2.5×10^{-8b}	8656+8176	7.7×10^{-4b}

^a *GRIN3A* is shown here because it was significant in the initial scan ($p=2.5 \times 10^{-8}$).

^b z-sc: The ENGAGE consortium provided the effect size on the z-scale.

For abbreviations and explanations, see Table 1.